AUTHOR INDEX TO VOLUME 120

Abbiati R. *See* Marchesini G
Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S. LST-2, A Human Liver-Specific Organic Anion Transporter, Determines Methotrexate Sensitivity in the Gastrointestinal Cancers, 120:1689
Abou-Saif A, Lei J, McDonald TJ, Chakrabarti S, Waxman IF, Shojamanesh H, Schrump DS, Kleiner DE, Gibril F, Jensen RT. A New Cause of Zollinger-Ellison Syndrome: Non-Small Cell Lung Cancer, 120:1271–cr
Abraczinskas DA. *Liver Disease: Diagnosis and Management*, 120:584–pmr
Abrahams TP. *See* McDermott CM
Adachi H. *See* Abe T
Adkisson W. *See* Corley DA
Adrian TE. *See* Schneider MB
Aepinus C. *See* Sotlar K
AGA Technical Review on the Evaluation of Food Allergy in Gastrointestinal Disorders, 120:1026–aga
Ahnen DJ. *See* Lieberman DA
Akita K. *See* Okuno M
Alberts DS. *See* Martínez ME
Albillos A. *See* Pérez-Páramo M
Albillos A, Pérez-Páramo M, Muñoz J. Prokinetics Reduce Bacterial Translocation in Cirrhosis: Will Sweeping the Gut Keep the Fluid Clean? Reply, 120:315–ss
Albright C. *See* Veltkamp C
Algoufi T. *See* Huizinga JD
Allemeyer EH. *See* Heuschen UA
Alter HJ. *See* Farci P
Amadesi S. *See* McRoberts JA
Amaral J, Xiao Z-L, Chen Q, Yu P, Biancani P, Behar J. Gallbladder Muscle Dysfunction in Patients With Chronic Acalculous Disease, 120:506
Ambs S. *See* Hussain SP
Amedei A. *See* D'Elios MM
American Gastroenterological Association Medical Position Statement: Celiac Sprue, 120:1522–aga
American Gastroenterological Association Medical Position Statement: Guidelines for the Evaluation of Food Allergies, 120:1023–aga
American Gastroenterological Association Medical Position Statement: Nausea and Vomiting, 120:261–aga
Amo A del. *See* León F
Amodio P. *See* Marchesini G
Amstad P. *See* Hussain SP
Anderson DC. *See* Sans M
Anderson JM. *See* Rahner C
Anderson MA. *See* Buttar NS
Andersson M. *See* Järnerot G
Andreu V. *See* Escorsell A
Angulo P, Lindor KD. Insulin Resistance and Mitochondrial Abnormalities in NASH: A Cool Look Into a Burning Issue, 120:1281–e
Anthony A. Why the Mesenteric Margin?, 120:1885–c
Antignac C. *See* Guillem P
Anton-Culver H. *See* Theuer CP
Antonioli DA. *See* Bitton A
Apolone G. *See* Marchesini G
Appelmelk BJ. *See* D'Elios MM
Arakawa Y. *See* Shiratori Y
Aranha G. *See* Schnell TG
Arase Y. *See* Ikeda K
Archambault A. *See* Sandborn WJ
Archimandritis A, Blatsos V, Skandalis N. Image of the Month, 120:336–im
Arias IM. *See* Ortiz D
Ariel A. *See* Chowers Y
Armiraglio E. *See* Barisani D
Arrese M, Karpen SJ. Bile Acids Regulate Their Own Synthesis: The Nuclear Connection. Comment, 120:1557–ss
Arruda SMB de, Passaro DJ, Yang S, Parsonnet J. Variability of Serologic Testing for *H. pylori* Using U.S. and Peruvian Antigens, 120:325–c
Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-Utility of Initial Medical Management for Crohn's Disease Perianal Fistulae, 120:1640
Artinger M. *See* Grossmann J
Arvand M. *See* Schmidt W
Arvelo F. *See* Bras-Gonçalves RA
Asaka M. *See* Sugiyama T
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Nijima A, Fujino MA, Kasuga M. Ghrelin Is an Appetite-Stimulatory Signal From Stomach With Structural Resemblance to Motilin, 120:337–rc
Asano N. *See* Abe T
Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. The Hepatitis B Vaccine: Sorting Through the B.S. About M.S., 120:1880–ss
Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family History as a Risk for Colorectal Cancer in Inflammatory Bowel Disease, 120:1356
Atchison CR. *See* Treinen-Moslen M
Atherton CT. *See* Wight NJ
Audrain S. *See* Cézard JP
Audrezet M-P. *See* Chen J-M
Augenlicht LH. *See* Mariadason JM
Ausina V. *See* Pérez-Páramo M
Autschbach F. *See* Heuschen UA
Auwex J. *See* Lu TT
Azar N. *See* Condat B
Azzaroli F. *See* Mehal WZ
Azzurri A. *See* D'Elios MM

Backman V. *See* Georgakoudi I
Bacon BR. Hemochromatosis: Diagnosis and Management, 120:718
Badizadegan K. *See* Georgakoudi I
Bain C, Fatmi A, Zoulim F, Zarski J-P, Trépo C, Inchauspé G. Impaired Allostimulatory Function of Dendritic Cells in Chronic Hepatitis C Infection, 120:512
Bajaj-Elliott M. *See* Pollok RCG
Baker JP. *See* Sandborn WJ
Balestrieri A. *See* Farci P
Balian A. *See* Veyradier A
Balish E. *See* Veltkamp C
Bandi JC. *See* Escorsell A
Bar-Meir S. *See* Chowers Y
Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett P, Collins SM. Role of Immunologic Factors and Cyclooxygenase 2 in Persistent Postinfective Enteric Muscle Dysfunction in Mice, 120:1729
Barhanin J. *See* Grahammer F
Barisani D, Parafioriti A, Armiraglio E, Meneveri R, Conte D. Duodenal Expression of a Putative Stimulator of Fe Transport and Transferrin Receptor

KEY TO ABBREVIATIONS

aga—American Gastroenterological Association
c—Correspondence
ce—Comment From the Editors
cr—Case Reports
gn—Gastroenterology News
e—Editorials
im—Image of the Month
pmr—Print and Media Reviews
rc—Rapid Communications
ss—Selected Summaries
srr—Special Reports and Reviews
tmig—This Month in Gastroenterology
vidd—Viewpoints in Digestive

in Anemia and Hemochromatosis, 120:1404
Barmada MM. *See* Pfützer R
Barnard J. Epidermal Growth Factor Receptor Blockade: An Emerging Therapeutic Modality in Gastroenterology, 120:1872–e
Barrett KE. The Yin and Yang of Intestinal Differentiation: Key Roles for Lipid Signaling, 120:1543–e
Barrow RK. *See* Watkins CC
Barry MJ. *See* Taylor KD
Barshack I. *See* Chowers Y
Bartek J. *See* Bartkova J
Bartkova J, Thullberg M, Slezak P, Jaramillo E, Rubio C, Thomassen LH, Bartek J. Aberrant Expression of G1-Phase Cell Cycle Regulators in Flat and Exophytic Adenomas of the Human Colon, 120:1680
Bartoli R. *See* Pérez-Páramo M
Batra AK. *See* Bonkovsky HL
Baumann E. *See* Stern HS
Beaugerie L. *See* Cosnes J
Beaugrand M. *See* Degoul F
Beaulieu J-F. *See* Deschênes C
Becker M. *See* Witt H
Beejay U. *See* Stone CD
Beglinger C. *See* Degen LP
Behar J. *See* Amaral J
Bélaïche J. *See* Laharie D
Belghiti J
See Condat B
See Laurent-Puig P
Bellaiche M. *See* Cézard JP
Benagiano M. *See* D'Elios MM
Bendia E. *See* Benedetti A
Benedetti A, Di Sario A, Casini A, Ridolfi F, Bendia E, Pigini P, Tonnini C, D'Ambrosio L, Feliciangeli G, Macarri G, Svegliati-Baroni G. Inhibition of the Na^+/H^+ Exchanger Reduces Rat Hepatic Stellate Cell Activity and Liver Fibrosis: An In Vitro and In Vivo Study, 120:545
Benhamou JP. *See* Condat B
Benjaminov F, Wong F, Blendis L, Halpern Z. Treatment of Hepatoportal Venous Thrombosis: The Role of Anticoagulation. Comment, 120: 578–ss
Bennett BL. *See* Hatano E
Bennett WP. *See* Hussain SP
Benninga MA. *See* van Ginkel R
Benos DJ. *See* Fuller CM
Bercik P. *See* Huizinga JD
Berčík P, Kučera P. Organization of Intestinal Pacemakers. Reply, 120: 320–c
Berends MJW. *See* Wu Y
Berezin I. *See* Huizinga JD
Bergamaschi G, Rolandi V, Cazzola M. Differential HFE Allele Expression in Hemochromatosis Heterozygotes, 120: 1309–c
Berger A. *See* Torrisani J
Berman MP. *See* D'Elios MM
Bernard O. *See* Jacquemin E
Bernstein CN. *See* Sandborn WJ
Berr F. *See* Wiese M
Berr F, Wiese M. The Road Not Taken. Reply, 120:1880–ss
Berstad AE, Hogåsen K, Bukholm G, Moran AP, Brandtzaeg P. Complement Activation Directly Induced by *Helicobacter pylori*, 120: 1108
Bessa X, Elizalde JI, Boix L, Piñol V, Lacy AM, Saló J, Piqué JM, Castells A. Lack of Prognostic Influence of Circulating Tumor Cells in Peripheral Blood of Patients With Colorectal Cancer, 120:1084
Bhagat L. *See* Singh VP
Bharucha AE. *Gastrointestinal Motility*, 120: 1056–pmr
Bhattacharyya AK. *See* Martínez ME
Biancani P. *See* Amaral J
Bianchi G. *See* Marchesini G
Billiar TR. *See* Jaiswal M
Binder HJ. *See* Geibel JP
Binder SW. *See* Hassard PV
Binot F. *See* Laurent-Puig P
Bioulac-Sage P. *See* Laurent-Puig P
Bissonnette M. *See* Cerda SR
Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, deB Edwardes MD, Stevens AC. Clinical, Biological, and Histologic Parameters as Predictors of Relapse in Ulcerative Colitis, 120:13
Björkhem I. *See* Pandak WM
Black JD. Protein Kinase C Isozymes in Colon Carcinogenesis: Guilt by Omission, 120:1868–e
Blackburn GL. *See* Mun EC
Blackshaw S. *See* Watkins CC
Blackstone MO. *Inner Hygiene: Constipation and the Pursuit of Health in Modern Society*., 120:317–pmr
Blatsos V. *See* Archimandritis A
Bleich M. *See* Grahammer F
Blendis L. *See* Benjaminov F
Blendis L, Halpern Z, Oren R. The Prevention of Hepatocellular Carcinoma by Interferon: The Story Continues. Comment, 120:1302–ss
Blennerhassett P. *See* Barbara G
Blumberg RS. *See* Nakajima A
Blumenthall A. *See* Stern HS
Bluteau O. *See* Laurent-Puig P
Bode JG. *See* Fischer R
Bodian C. *See* Friedman S
Boeckxstaens GE. *See* van Ginkel R
Boeker KHW. *See* Tillmann HL
Bohdan P. *See* Pandak WM
Boileau AC. *See* Richmond BL
Boix L. *See* Bessa X
Böker KHW. *See* Wedemeyer H
Boku K, Ohno T, Saeki T, Hayashi H, Hayashi I, Katori M, Murata T, Narumiya S, Saigenji K, Majima M. Adaptive Cytoprotection Mediated by Prostaglandin I_2 Is Attributable to Sensitization of CGRP-Containing Sensory Nerves, 120:134
Boland CR, Yamada T. Our New President-Jon I. Isenberg, M.D., 120: 1518–aga
Bond JH. *See* Lieberman DA
Bonkovsky HL, Batra AK. *Atlas of the Liver*, 120:1305–pmr
Bootello A. *See* León F
Borsukova H. *See* Drobnik W
Bosch J. *See* Escorsell A
Bosma PJ. *See* Jacquemin E
Bossuyt X. *See* Vermeire S
Boudet MJ. *See* Condat B
Bouisson M. *See* Torrisani J
Bouma BE. *See* Poneros JM
Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride Accelerates Gastrointestinal and Colonic Transit in Patients With Constipation Without a Rectal Evacuation Disorder, 120:354
Bousvaros A. *See* Bitton A
Bradford BU. *See* Enomoto N
Brand S. *See* Poneros JM
Brandenburg VM, Frank RD, Wasmuth HE, Gartung C. Increased Levels of Factor VIII:C as a Possible Risk Factor for Portal, Splenic, and Mesenteric Vein Thrombosis, 120:1563–c
Brandtzaeg P. *See* Berstad AE
Bras-Gonçalves RA, Pocard M, Formento J-L, Poirson-Bichat F, Pinieux G de, Pandrea I, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Lesuffleur T, Dutrillaux B, Poupon M-F. Synergistic Efficacy of 3*n*-Butyrate and 5-Fluorouracil in Human Colorectal Cancer Xenografts via Modulation of DNA Synthesis, 120:874
Brasitus TA
See Cerda SR
Braun J, Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR. Optimal Cases and Sites to Search for Primary Microbial Agents in Crohn's Disease. Reply, 120:1066–c

Brembeck FH, Moffett J, Wang TC, Rustgi AK. The Keratin 19 Promoter Is Potent for Cell-Specific Targeting of Genes in Transgenic Mice, 120:1720
Brenner DA
See Enomoto N
See Hatano E
Brewster WR. *See* Theuer CP
Brodovicz K. *See* Ascherio A
Broström O. *See* Askling J
Browning J. *See* Debard N
Buchan AMJ, Squires PE, Ring M, Meloche RM. Mechanism of Action of the Calcium-Sensing Receptor in Human Antral Gastrin Cells, 120:1128
Büchler C. *See* Drobnik W
Bukholm G. *See* Berstad AE
Bull L. *See* Salen G
Bulone L. *See* Slonim AE
Bültmann B. *See* Sotlar K
Bunnett NW. *See* McRoberts JA
Burdelski M. *See* Jacquemin E
Burgart LJ. *See* Buttar NS
Burton DD. *See* Bouras EP
Buscail L. *See* Torrisani J
Butler K. *See* Gibb DM
Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ. Extent of High-Grade Dysplasia in Barrett's Esophagus Correlates With Risk of Adenocarcinoma, 120:1630
Buys CHCM. *See* Wu Y
Buzoni-Gatel D, Debbabi H, Mennechet FJD, Martin V, Lepage AC, Schwartzman JD, Kasper LH. Murine Ileitis After Intracellular Parasite Infection Is Controlled by TGF-β-Producing Intraepithelial Lymphocytes, 120:914
Bytzer P. *See* Lassen A

Caballería J. *See* Cabré E
Cabré E. *See* Pérez-Páramo M
Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombraña JL, Parés A, Papo M, Planas R, Gassull MA. Nutritional Therapy for Alcoholic Hepatitis: New Life for an Old Idea, 120:1053–ss
Cadranel J-F. *See* Di Martino V
Cafferkey M. *See* Gibb DM
Cahalon L. *See* Chowers Y
Calder NA. *See* Wight NJ
Camacho-Lobato L. *See* Vela MF
Camarero C. *See* León F
Camilleri M
Management of the Irritable Bowel Syndrome, 120:652
See Bouras EP
Camilleri M, Podolsky DK. Postapproval Drug Surveillance and the First Principle of Medicine, 120:5–ce
Cammà C. *See* Cottone M
Campbell-Sargent C. *See* Sanyal AJ
Capellá G. *See* Torrisani J
Cappelli M. *See* Stern HS
Carbon C. *See* Sobhani I
Carbonnel F. *See* Cosnes J
Carey MC. *See* Lammert F
Carraway RE. *See* Gui X
Casini A. *See* Benedetti A
Castell DO. *See* Vela MF
Castells A. *See* Bessa X
Catassi C. *See* Fasano A
Cazzola M. *See* Bergamaschi G
Cello JP. *See* Corley DA
Cepanec C. *See* Degoul F
Cerbone AM. *See* Madonna P
Cerda SR, Bissonnette M, Scaglione-Sewell B, Lyons MR, Khare S, Mustafi R, Brasitus TA. PKC-δ Inhibits Anchorage-Dependent and -Independent Growth, Enhances Differentiation, and Increases Apoptosis in CaCo-2 Cells, 120:1700
Cézard JP, Duhamel JF, Meyer M, Pharaon I, Bellaiche M, Maurage C, Ginies JL, Vaillant JM, Girardet JP, Lamireau T, Poujol A, Morali A, Sarles J, Olives JP, Whately-Smith C, Audrain S, Lecomte JM. Efficacy and Tolerability of Racecadotril in Acute Diarrhea in Children, 120:799
Chaban VV. *See* McRoberts JA
Chakrabarti S. *See* Abou-Saif A
Chamouard P. G20210A Prothrombin Gene Mutation and Other Trombophilic Polymorphisms in Patients With Portal or Hepatic Venous Thrombosis. Reply, 120:1060–c
Chang CS. *See* Huang YH
Chang EB. *See* Sugi K
Chapman R. *See* Norris S
Chaput J-C. *See* Veyradier A
Chayama K. *See* Ikeda K
Chejfec G
See Lieberman DA
See Schnell TG
Chen D-S. *See* Kao J-H
Chen GH. *See* Huang YH
Chen J-M, Marcier B, Audrezet M-P, Raguenes O, Quere I, Ferec C. Mutations of the Pancreatic Secretory Trypsin Inhibitor (PSTI) Gene in Idiopathic Chronic Pancreatitis, 120:1061–c
Chen Q. *See* Amaral J
Chen X-M, Levine SA, Splinter PL, Tietz PS, Ganong AL, Jobin C, Gores GJ, Paya CV, LARusso NF. *Cryptosporidium parvum* Activates Factor κB in Biliary Epithelia Preventing Epithelial Cell Apoptosis, 120:1774
Chey WD. *See* Ladabaum U
Chiba M, Nakamura T, Hoshina S, Kitagawa Y. Optimal Cases and Sites to Search for Primary Microbial Agents in Crohn's Disease, 120:1066–c
Chien DY. *See* Farci P
Chowers Y, Lider O, Schor H, Barshack I, Tal R, Ariel A, Bar-Meir S, Cohen IR, Cahalon L. Disaccharides Derived From Heparin or Heparin Sulfate Regulate IL-8 and IL-1β Secretion by Intestinal Epithelial Cells, 120:449
Christie GR, Ford D, Howard A, Clark MA, Hirst BH. Glycine Supply to Human Enterocytes Mediated by High-Affinity Basolateral GLYT1, 120:439
Cianchi F. *See* D'Elios MM
Ciclitira PJ. AGA Technical Review on Celiac Sprue, 120:1526–aga
Cilley RE. *See* Teitelbaum DH
Clare M. *See* Norris S
Clark MA. *See* Christie GR
Clore JN. *See* Sanyal AJ
Cohard M. *See* Deviére J
Cohen A. *See* Bitton A
Cohen IR. *See* Chowers Y
Cohen RD. Intravenous Cyclosporine in Severe Ulcerative Colitis: Ready to Stand Alone?, 120:1541–e
Cohen-Solal L. *See* Guillem P
Cohn SM. *See* Arseneau KO
Coiana A. *See* Farci P
Collet A. *See* Degen LP
Collins R. *See* Norris S
Collins SM
See Barbara G
See Huizinga JD
Colombel J-F. *See* Laharie D
Colucci G. *See* Mulé F
Cominelli F. *See* Arseneau KO
Compton CC. *See* Poneros JM
Condat B, Pessione F, Denninger MH, Hillaire S, Valla D, Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, Boudet MJ, Hay JM, Erlinger S, Benhamou JP, Belghiti J, Valla D. Treatment of Hepatoportal Venous Thrombosis: The Role of Anticoagulation, 120:578–ss
Condat B, Pessione F, Hillaire S, Denninger MH, Guillin M-C, Poliquin M, Hadengue A, Erlinger S, Valla D. Current Outcome of Portal Vein Thrombosis in Adults: Risk and Benefit of Anticoagulant Therapy, 120:490

Condat B, Zeitoun G, Valla D. Treatment of Hepatoportal Venous Thrombosis: The Role of Anticoagulation. Reply, 120:579–ss
Connor HD. *See* Wheeler MD
Connors AF Jr. *See* Arseneau KO
Conrad PG. *See* Terdiman JP
Conte D. *See* Barisani D
Contos MJ. *See* Sanyal AJ
Coplan PM. *See* Ascherio A
Coppola A. *See* Madonna P
Coquelle A. *See* Bras-Gonçalves RA
Corinaldesi R. *See* Tonini M
Corley DA, Cello JP, Adkisson W, Ko W-F, Kerlikowske K. Octreotide for Acute Esophageal Variceal Bleeding: A Meta-analysis, 120:946
Cortot A. *See* Laharie D
Cosnes J, Beaugerie L, Carbonnel F, Gendre J-P. Smoking Cessation and the Course of Crohn's Disease: An Intervention Study, 120:1093
Cote J. *See* Wight NJ
Cottone M, Cammà C. Mesalamine Maintenance Therapy for Crohn's Disease. Reply, 120:585–c
Coulie BJ, Miller LJ. Identification of Motilin-Related Peptide, 120:588–c
Couse T. *See* Shibahara T
Coutinho S. *See* McRoberts JA
Cox TM. *See* Griffiths WJH
Crawley SC. *See* Terdiman JP
Crema F. *See* Tonini M
Crémieux A-C. *See* Sobhani I
Creminon C. *See* McRoberts JA
Cresteil D. *See* Jacquemin E
Crispe IN. *See* Mehal WZ
Crosby HA, Kelly DA, Strain AJ. Human Hepatic Stem-like Cells Isolated Using *c-kit* or CD34 Can Differentiate Into Biliary Epithelium, 120:534
Cross D. *See* Ladabaum U
Czaja AJ, Homburger HA. Autoantibodies in Liver Disease, 120:239–srr

DACosta CM. *See* Williams KL
Dagher I. *See* Veyradier A
D'Agostino G. *See* Tonini M
Dallob A. *See* Wight NJ
Dalwadi H. *See* Braun J
D'Ambrosio L. *See* Benedetti A
Damore MB. *See* Slonim AE
Danese S. *See* Papa A
Date F. *See* Abe T
Davidson RD. *See* Salto-Tellez M
De Giorgio R. *See* Barbara G
de Vree JML. *See* Jacquemin E
deB Edwardes MD. *See* Bitton A
Debard N, Sierro F, Browning J, Kraehenbuhl J-P. Effect of Mature Lymphocytes and Lymphotoxin on the Development of the Follicle-Associated Epithelium and M Cells in Mouse Peyer's Patches, 120:1173
Debbabi H. *See* Buzoni-Gatel D
Debeugny S. *See* Laharie D
DeBiase F. *See* Sorrentino D
Degen LP, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, Larsen F, Beglinger C, Hildebrand P. Blockade of GRP Receptors Inhibits Gastric Emptying and Gallbladder Contraction but Accelerates Small Intestinal Transit, 120:361
Degott C. *See* Degoul F
Degoul F, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, Beaugrand M, Valla D, Pessayre D. Homozygosity for Alanine in the Mitochondrial Targeting Sequence of Superoxide Dismutase and Risk for Severe Alcoholic Liver Disease, 120:1468
Deibert D. *See* Rössle M
Delcambre F. *See* Guillem P
D'Elios MM, Berman MP, Azzurri A, Amedei A, Benagiano M, Pont JJ de, Cianchi F, Vandenbroucke-Grauls CM, Romagnani S, Appelmelk BJ, Prete G del. H^+,K^+-ATPase (Proton Pump) Is the Target Autoantigen of Th1-Type Cytotoxic T Cells in Autoimmune Gastritis, 120:377
Deng Y. *See* Barbara G
Denninger MH. *See* Condat B
Der T. *See* Huizinga JD
Deschênes C, Vézina A, Beaulieu J-F, Rivard N. Role of $p27^{Kip1}$ in Human Intestinal Cell Differentiation, 120:423
DeVault KR. *Gastroesophageal Reflux Disease*, 120:583–pmr
Deviére J, Le Moine O, Van Laethem J-L, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 Reduces the Incidence of Pancreatitis After Therapeutic Endoscopic Retrograde Cholangiopancreatography, 120:498
Dewar D. *See* Stern HS
D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous Cyclosporine Versus Intravenous Corticosteroids as Single Therapy for Severe Attacks of Ulcerative Colitis: A Randomized Controlled Trial, 120:1323
Di Martino V, Rosenheim M, Dorent R, Opolon P, Cadranel J-F, Gandjbachkh I, Lunel F. Hepatitis B Infection in Heart Transplant Recipients. Reply, 120:1313–c
Di Sario A. *See* Benedetti A
Diaz G. *See* Farci P
Dickman PW. *See* Askling J
Diehl AM. Sugar Pills for Pancreatic Cancer: The Benefits of Becoming Sensitive, 120:1291–e
Dieleman LA. *See* Williams KL
Dietschy JM. *See* Repa JJ
Ding X-Z. *See* Schneider MB
Dockray GJ. Transepithelial Signaling: Making Sense of Stomach Contents, 120:1279–e
Domchek SM. *Selected Topics in Clinical Oncology*, 120:583–pmr
Donaldson P. *See* Norris S
Donnelly G. *See* Huizinga JD
Doo E, Liang TJ. Molecular Anatomy and Pathophysiologic Implications of Drug Resistance in Hepatitis B Virus Infection, 120:1000–srr
Dorent R. *See* Di Martino V
Dowling RH, Thomas LA. Intestinal Motility and Bacterial Overgrowth in Patients With Gallstones. Reply, 120:1311–c
Drobnik W, Lindenthal B, Lieser B, Ritter M, Weber TC, Liebisch G, Giesa U, Igel M, Borsukova H, Büchler C, Fung-Leung WP, Von Bergmann K, Schmitz G. ATP-Binding Cassette Transporter A1 (ABCA1) Affects Total Body Sterol Metabolism, 120:1203
DuBois RN. *See* Mann M
Duhamel JF. *See* Cézard JP
Dumont M. *See* Jacquemin E
Dunn DT. *See* Gibb DM
Dupas J-L. *See* Laharie D
Dutrillaux B. *See* Bras-Gonçalves RA
Dwinell MB, Lügering N, Eckmann L, Kagnoff MF. Regulated Production of Interferon-Inducible T-Cell Chemoattractants by Human Intestinal Epithelial Cells, 120:49

Eastburn K. *See* Merlin D
Eckmann L. *See* Dwinell MB
Eggertsen G. *See* Pandak WM
Eiras P. *See* León F
Eisendrath P. *See* Deviére J
Ekbom A. *See* Askling J
Ekstrand J. *See* McDermott CM
El Younsi M. *See* Condat B
Elena M. *See* Sans M
Elizalde JI. *See* Bessa X
Elsaleh H, Shannon B, Iacopetta B. Microsatellite Instability as a Molecular Marker for Very Good Survival in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy, 120:1309–c
Ennes HS. *See* McRoberts JA

Enomoto A. *See* Enomoto N
Enomoto N, Ikejima K, Yamashina S, Enomoto A, Nishiura T, Nishimura T, Brenner DA, Schemmer P, Bradford BU, Rivera CA, Zhong Z, Thurman RG. Alcoholic Steatosis: The Kupffer Cell A Villain?, 120:581–ss
Erlinger S. *See* Condat B
Ertan A. *See* Younes M
Escolano S. *See* Condat B
Escorsell A, Bandi JC, Andreu V, Moitinho E, García-Pagán JC, Bosch J, Rodés J. Desensitization to the Effects of Intravenous Octreotide in Cirrhotic Patients With Portal Hypertension, 120:161
Etemad B, Whitcomb DC. Chronic Pancreatitis: Diagnosis, Classification, and New Genetic Developments, 120:682
Evers BM. *See* Wang Q

Falk W. *See* Steidler L
Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. Predicting the Outcome of Hepatitis C Virus Infection, 120:312–ss
Farthing MJG. *See* Pollok RCG
Fasano A, Catassi C. Current Approaches to Diagnostic and Treatment of Celiac Disease: An Evolving Spectrum, 120:636
Fatmi A. *See* Bain C
Fattinger K. *See* Kullak-Ublick GA
Feagan BG. *See* Sandborn WJ
Feagan BG, Fedorak RN, Irvin EJ. Methotrexate for the Maintenance of Remission in Crohn's Disease, 120:1553–ss
Feagan BG, McDonald JWD. Mesalamine Maintenance Therapy for Crohn's Disease, 120:585–c
Fedorak RN. *See* Feagan BG
Feinle C, Rades T, Otto B, Fried M. Fat Digestion Modulates Gastrointestinal Sensations Induced by Gastric Distention and Duodenal Lipid in Humans, 120:1100
Feld DMS. *See* Georgakoudi I
Feliciangeli G. *See* Benedetti A
Ferec C. *See* Chen J-M
Ferris CD
  Are Things Looking Up for the Treatment of Gastroparesis? Sildenafil in Animal Models of Diabetic Gastropathy. Reply, 120:577–ss
  See Watkins CC
Fiasse R. *See* Laharie D
Fickert P. *See* Trauner M
Field M. *See* Sugi K
Fiers W. *See* Steidler L
Finn AL, Kuzhikandathil EV, Oxford GS, Itoh-Lindstrom Y. Sucrase-Isomaltase Is an Adenosine 3',5'-Cyclic Monophosphate-Dependent Epithelial Chloride Channel, 120:117
Fiocchi C. *See* Grossmann J
Fischer R, Schmitt M, Bode JG, Häussinger D. Expression of the Peripheral-type Benzodiazepine Receptor and Apoptosis Induction in Hepatic Stellate Cells, 120:1212
Fisher RS. *See* Friedel D
Fitch MD. *See* Jorgensen JR
Fitzgerald P. *See* Huizinga JD
Fitzgerald RC, Lovat L. Significance of Genetic Abnormalities After Photodynamic Therapy, 120:1064–c
Fleming SE. *See* Jorgensen JR
Folwaczny C. Heparin Therapy for Ulcerative Colitis, 120:1307–c
Foody W, Heuman DD, Mihas AA, Schubert ML. Nutritional Therapy for Alcoholic Hepatitis: New Life for an Old Idea. Comment, 120:1053–ss
Ford D. *See* Christie GR
Formento J-L. *See* Bras-Gonçalves RA
Fox MR. Intractable Insomnia After Cessation of Treatment With Thalidomide, 120:1567–c
Franco D. *See* Laurent-Puig P
Frank RD. *See* Brandenburg VM
Franklund C. *See* Pandak WM
Franzén L. *See* Järnerot G
Freeman MW. *See* Rigotti A
Freile I. *See* Pérez-Páramo M
Fricke J. *See* Mulé F
Fried M. *See* Feinle C
Friedel D, Thomas R, Fisher RS. Ischemic Colitis During Treatment With Alosetron, 120:557–cr
Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and Surveillance Colonoscopy in Chronic Crohn's Colitis, 120:820
Froh M. *See* Wheeler MD
Fromenty B. *See* Degoul F
Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Iino S, Kimura S, Koike K. Hepatitis B Virus Genotypes and Hepatocellular Carcinoma in Japan, 120:1564–c
Fujimiya M. *See* Asakawa A
Fujino MA. *See* Asakawa A
Fujiwara K. *See* Abe T
Fujiyama S. *See* Shiratori Y
Fuller CM, Benos DJ. Identification of a New Chloride Channel: A Sweet Story?, 120:299–e
Fuller CR. *See* Williams KL
Fung-Leung WP. *See* Drobnik W
Furness JB. *See* Southwell BR
Furuta K. *See* Harada M

Galardi LB. *See* Lu TT
Gandjbachkh I. *See* Di Martino V
Ganong AL. *See* Chen X-M
García-Pagán JC. *See* Escorsell A
García-Tsao G
  Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis, 120:726
  Prokinetics Reduce Bacterial Translocation in Cirrhosis: Will Sweeping the Gut Keep the Fluid Clean? Comment, 120:314–ss
Garewal H. *See* Lieberman DA
Garlick NM. *See* Wight NJ
Gartung C. *See* Brandenburg VM
Gasbarrini A. *See* Papa A
Gasbarrini G. *See* Papa A
Gassull M. *See* Pérez-Páramo M
Gassull MA. *See* Cabré E
Gatalica Z. *See* Saitoh Y
Gaylinn BD. *See* Rincon JP del
Geboes K. *See* D'Haens G
Geibel JP, Rajendran VM, Binder HJ. Na^+-Dependent Fluid Absorption in Intact Perfused Rat Colonic Crypts, 120:144
Gendre J-P. *See* Cosnes J
Georgakoudi I, Jacobson BC, Van Dam J, Backman V, Wallace MB, Müller MG, Zhang Q, Badizadegan K, Sun D, Thomas GA, Perelman LT, Feld DMS. Fluorescence, Reflectance, and Light-Scattering Spectroscopy for Evaluating Dysplasia in Patients With Barrett's Esophagus, 120:1620
Geppetti P. *See* McRoberts JA
Gerbes A, Rössle M. Management of Refractory Ascites: Are Tips or Taps Tops? Reply, 120:312–ss
Gerbes AL. *See* Rössle M
Gershwin ME. *See* Kita H
Gertz BJ. *See* Wight NJ
Ghilain A. *See* Deviére J
Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, Butler K. Cesarian for C? Possibly. . ., 120:1555–ss
Gibril F. *See* Abou-Saif A
Gibson PR. *See* Mariadason JM
Giesa U. *See* Drobnik W
Ginies JL. *See* Cézard JP
Giorgio R de. *See* Tonini M
Girardet JP. *See* Cézard JP

Giraud V. *See* Veyradier A
Gironella M. *See* Sans M
Glinghammar B, Rafter J. Colonic Luminal Contents Induce Cyclooxygenase 2 Transcription in Human Colon Carcinoma Cells, 120:401
Golberg T. *See* Slonim AE
Gold R. *See* Kojic EM
Goldstein E. *See* Friedman S
Goodall RL. *See* Gibb DM
Goodwin B. *See* Lu TT
Gordon D. Gastroenterology News, 120:3–gn, 120:333–gn, 120:785–gn
Gores GJ
See Chen X-M
See Jaiswal M
See Takikawa Y
Gottesdiener K. *See* Wight NJ
Gower-Rousseau C. *See* Laharie D
Grady EF. *See* McRoberts JA
Graff J. *See* Jeppesen PB
Grahammer F, Herling AW, Lang HJ, Schmitt-Gräff A, Wittekindt OH, Nitschke R, Bleich M, Barhanin J, Warth R. The Cardiac K^+ Channel KCNQ1 Is Essential for Gastric Acid Secretion, 120:1363
Grandbastien B. *See* Laharie D
Granholm NA. *See* Richmond BL
Grasso AW. *See* Grossmann J
Grenther WB. *See* Veltkamp C
Gressner AM. The Up-and-Down of Hepatic Stellate Cells in Tissue Injury: Apoptosis Restores Cellular Homeostasis, 120:1285–e
Griffiths WJH, Sly WS, Cox TM. Intestinal Iron Uptake Determined by Divalent Metal Transporter Is Enhanced in HFE-Deficient Mice With Hemochromatosis, 120:1420
Groenen P. *See* Vermeire S
Grossmann J, Artinger M, Grasso AW, Kung H-J, Schölmerich J, Fiocchi C, Levine AD. Hierarchical Cleavage of Focal Adhesion Kinase by Caspases Alters Signal Transduction During Apoptosis of Intestinal Epithelial Cells, 120:79
Groszmann RJ. *See* Wiest R
Gui X, Carraway RE. Enhancement of Jejunal Absorption of Conjugated Bile Acid by Neurotensin in Rats, 120:151
Guillem P, Delcambre F, Cohen-Solal L, Triboulet J-P, Antignac C, Heidet L, Quandalle P. Diffuse Esophageal Leiomyomatosis with Perirectal Involvement Mimicking Hirschsprung Disease, 120:216–cr
Guillin M-C. *See* Condat B
Gülberg V. *See* Rössle M
Gum JR Jr. *See* Terdiman JP
Hadchouel M. *See* Jacquemin E
Hadengue A. *See* Condat B
Hagenbuch B. *See* Kullak-Ublick GA
Hahn EG. *See* Schreiber S
Haile DJ. *See* Zoller H
Haldeman KM. *See* Williams KL
Halpern Z
See Benjaminov F
See Blendis L
Ham A-J. *See* Hussain SP
Han S. *See* Saab S
Hanada S. *See* Harada M
Hanauer SB. *See* Sandborn WJ
Hans W. *See* Steidler L
Hansen BS. *See* Jeppesen PB
Haorah J. *See* Schneider MB
Harada M, Sakisaka S, Terada K, Kimura R, Kawaguchi T, Koga H, Kim M, Taniguchi E, Hanada S, Suganuma T, Furuta K, Sugiyama T, Sata M. A Mutation of the Wilson Disease Protein, ATP7B, Is Degraded in the Proteasomes and Forms Protein Aggregates, 120:967
Harpaz N. *See* Friedman S
Harris CC. *See* Hussain SP
Harrison P. *See* Norris S
Hartmann B. *See* Jeppesen PB
Hasler WL
Are Things Looking Up for the Treatment of Gastroparesis? Sildenafil in Animal Models of Diabetic Gastropathy. Comment, 120:576–ss
See Ladabaum U
See Quigley EMM
Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-Tumor Necrosis Factor Monoclonal Antibody Therapy for Gastrointestinal Behçet's Disease: A Case Report, 120:995–cr
Hata S. *See* Maeyama H
Hatano E, Bennett BL, Manning AM, Qian T, Lemasters JJ, Brenner DA. NF-κB Stimulates Inducible Nitric Oxide Synthase to Protect Mouse Hepatocytes From TNF-α- and Fas-Mediated Apoptosis, 120:1251
Häussinger D
Liver Fibrosis and Na^+/H^+ Exchange, 120:572–e
See Fischer R
Hawkey C. *See* Sandborn WJ
Hawkey CJ. *See* Wight NJ
Hay JM. *See* Condat B
Hayashi H. *See* Boku K
Hayashi I. *See* Boku K
Healy M. *See* Gibb DM
Heath PK. *See* Sandborn WJ
Heathcote EJ. *See* Lok A
Hediger MA. *See* Merlin D
Heidet L. *See* Guillem P
Hemminki A, Joensuu H. Microsatellite Instability as a Molecular Marker for Very Good Survival in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy. Reply, 120:1309–c
Henin D. *See* Sobhani I
Hennies HC. *See* Witt H
Hepburn M. *See* Terdiman JP
Herfarth C. *See* Heuschen UA
Herling AW. *See* Grahammer F
Hermelin B. *See* Rosmorduc O
Hernán MA. *See* Ascherio A
Hernandez A. *See* Wang Q
Herrmann E. *See* Mulé F
Hervatin F. *See* Sobhani I
Heuman DD. *See* Foody W
Heuschen G. *See* Heuschen UA
Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, Herfarth C, Heuschen G. Backwash Ileitis Is Strongly Associated With Colorectal Carcinoma in Ulcerative Colitis, 120:841
Hewlett B. *See* Huizinga JD
Heyman RA. *See* Repa JJ
Hidaka E. *See* Maeyama H
Hiele M. *See* D'Haens G
Hietaranta AJ. *See* Singh VP
Hildebrand P. *See* Degen LP
Hillaire S. *See* Condat B
Hinz U. *See* Heuschen UA
Hirano I, Tatum RP, Shi G, Sang Q, Joehl RJ, Kahrilas PJ. Manometric Heterogeneity in Patients With Idiopathic Achalasia, 120:789
Hiraoka S. *See* Miyazaki Y
Hirst BH. *See* Christie GR
Hofstra RMW. *See* Wu Y
Hogåsen K. *See* Berstad AE
Holl V. *See* Rössle M
Hollema H. *See* Wu Y
Holloway R. *See* Sifrim D
Holst JJ. *See* Jeppesen PB
Homburger HA. *See* Czaja AJ
Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential Gene Expression Between Chronic Hepatitis B and C Hepatic Lesion, 120:955
Hoofnagle JH. *See* Lok A
Hornby PJ. *See* McDermott CM
Hoshina S. *See* Chiba M
Houlston R. *See* Tomlinson I
Howard A. *See* Christie GR
Huang Y-H. *See* Yeh H-Z
Huang YH, Yeh HZ, Chen GH, Chang CS, Wu CY, Poon SK, Lien HC, Yang SS. Management of Gastric Varices, 120:1875–ss
Huber R. *See* Kullak-Ublick GA
Huggins KW. *See* Richmond BL
Hughes J. *See* Yadav D

Hui DY. *See* Richmond BL
Huizinga JD, Berezin I, Sircar K, Hewlett B, Donnelly G, Bercik P, Ross C, Algoufi T, Fitzgerald P, Der T, Riddell RH, Collins SM, Jacobson K. Development of Interstitial Cells of Cajal in a Full-Term Infant Without an Enteric Nervous System, 120: 561–cr
Hunter AGW. *See* Stern HS
Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham A-J, Swenberg JA, Marrogi AJ, Harris CC. p53 At The Crossroads of Colitis and Cancer, 120:1877–ss
Hyland N. *See* McDermott CM
Hylemon PB. *See* Pandak WM

Iacopetta B. *See* Elsaleh H
Igel M. *See* Drobnik W
Iijima Y. *See* Maeyama H
Iino S. *See* Fujie H
Iinuma K. *See* Abe T
Ikeda K. *See* Okuno M
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. The Prevention of Hepatocellular Carcinoma by Interferon: The Story Continues, 120:1302–ss
Ikeda K, Kumada H. The Prevention of Hepatocellular Carcinoma by Interferon: The Story Continues. Reply, 120:1303–ss
Ikejima K. *See* Enomoto N
Imazeki F. *See* Shiratori Y
Imperiale TF. *See* Lieberman DA
Imperiale TF, Ransohoff DF. What's Right and What's Left? Reply, 120:1050–ss
Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. What's Right and What's Left?, 120: 1049–ss
Inchauspé G. *See* Bain C
Inui A. *See* Asakawa A
Irvin EJ. *See* Feagan BG
Ishimura Y. *See* Kyokane T
Ismair MG. *See* Kullak-Ublick GA
Ito S. *See* Abe T
Itoh-Lindstrom Y. *See* Finn AL
Iwakiri D, Podolsky DK. Keratinocyte Growth Factor Promotes Goblet Cell Differentiation Through Regulation of Goblet Cell Silencer Inhibitor, 120: 1372

Jacobson BC
Atlas of Gastrointestinal Endoscopy & Endoscopic Biopsies, 120:1305–pmr
See Georgakoudi I
Jacobson K. *See* Huizinga JD
Jacquemin E, de Vree JML, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, Paul M, Burdelski M, Bosma PJ, Bernard O, Hadchouel M, Oude Elferink RPJ. The Wide Spectrum of Multidrug Resistance 3 Deficiency: From Neonatal Cholestasis to Cirrhosis of Adulthood, 120:1448
Jaffrey S. *See* Watkins CC
Jaiswal M, LARusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric Oxide-Mediated Inhibition of DNA Repair Potentiates Oxidative DNA Damage in Cholangiocytes, 120:190
Janoff EN, Smith PD. Emerging Concepts in Gastrointestinal Aspects of HIV-1 Pathogenesis and Management, 120: 607
Janssens J. *See* Sifrim D
Jaramillo E. *See* Bartkova J
Järnerot G, Andersson M, Franzén L. Laparoscopic Appendectomy in Patients With Refractory Ulcerative Colitis, 120:1562–c
Jensen RT. *See* Abou-Saif A
Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like Peptide 2 Improves Nutrient Absorption and Nutritional Status in Short-Bowel Patients With No Colon, 120:806
Jewell DP. *See* Vermeire S
Jobin C. *See* Chen X-M; Weaver SA
Joehl RJ. *See* Hirano I
Joensuu H. *See* Hemminki A
Jones SA. *See* Lu TT
Jong YP de. *See* Veltkamp C
Joossens S. *See* Vermeire S
Jorgensen JR, Fitch MD, Mortensen PB, Fleming SE. In Vivo Absorption of Medium-Chain Fatty Acids by the Rat Colon Exceeds That of Short-Chain Fatty Acids, 120:1152
Judge TA, Lichtenstein GR. Novel Medical Therapies for Crohn's Disease: Is There Room for Growth? Comment, 120:309–ss

Kadowaki T. *See* Nakajima A
Kaga T. *See* Asakawa A
Kagnoff MF. *See* Dwinell MB
Kahrilas PJ
Will Impedance Testing Rewrite the Book on GERD?, 120:1862–e
See Hirano I
Kajiyama M. *See* Maeyama H
Kakyo M. *See* Abe T
Kamm MA. *See* Sandborn WJ
Kandolf R. *See* Sotlar K
Kaneda K. *See* Okuno M
Kaneko S. *See* Honda M
Kao J-H, Chen D-S. Hepatitis B Virus Genotypes and Hepatocellular Carcinoma in Japan. Reply, 120:1565–c
Kapadia C. Alcoholic Steatosis: The Kupffer Cell A Villain? Comment, 120:582–ss
Kaplowitz N. Remembering John Walsh: One of the Prophets of GI, 120: 335–ce
Kärkkäinen P. *See* Rautemaa R
Karlén P. *See* Askling J
Karpen SJ. *See* Arrese M
Kasper LH. *See* Buzoni-Gatel D
Kasuga M. *See* Asakawa A
Katori M. *See* Boku K
Katsuyama T. *See* Maeyama H
Katz PO. *See* Vela MF
Kawada N. *See* Okuno M
Kawaguchi T. *See* Harada M
Kawai H. *See* Honda M
Kawamura N. *See* Maeyama H
Keeffe EB. Liver Transplantation: Current Status and Novel Approaches to Liver Replacement, 120:749
Kelly DA. *See* Crosby HA
Kempinga C. *See* Wu Y
Kerlikowske K. *See* Corley DA
Kerr TA. *See* Lu TT
Ketterer S. *See* Degen LP
Khare S. *See* Cerda SR
Kim J. *See* Braun J
Kim KE. This Month in GASTROENTEROLOGY, 120:1, 120:331, 120:783, 120:1317, 120: 1573
Kim M. *See* Harada M
Kim S. *See* Wang Q
Kim YS. *See* Terdiman JP
Kimura R. *See* Harada M
Kimura S. *See* Fujie H
Kita H, Mackay IR, Van de Water J, Gershwin ME. The Lymphoid Liver: Considerations on Pathways to Autoimmune Injury, 120:1485–srr
Kitagawa Y. *See* Chiba M
Kitamura S. *See* Miyazaki Y
Kleinbeuker JH. *See* Wu Y
Kleiner DE. *See* Abou-Saif A
Kliewer SA. *See* Lu TT
Knisely AS. *See* Salen G
Ko W-F. *See* Corley DA
Kobayashi K. *See* Honda M
Kobayashi M. *See* Ikeda K
Koch RO. *See* Zoller H
Koga H. *See* Harada M
Kohgo Y. *See* Saitoh Y
Koike K. *See* Fujie H

Kojic EM, Shah S, Gold R. Image of the Month, 120:1322–im
Kojima S. *See* Okuno M
Kokkola A. *See* Rautemaa R
Kolios G. *See* Weaver SA
Kondeatis E. *See* Norris S
Kondo TN. *See* Abe T
Kondo Y. *See* Abe T
Kono H. *See* Wheeler MD
Koretz RL
The Road Not Taken. Comment, 120: 1879–ss
What's Right and What's Left? Comment, 120:1049–ss
Köveker G. *See* Sotlar K
Kowdley KV. Is Hepatic Fibrosis Reversible With Therapy in Hepatitis C? Comment, 120:580–ss
Kraehenbuhl J-P. *See* Debard N
Krishnadath KK. *See* Buttar NS
Kruis W. *See* Schreiber S
Krummenerl T. *See* Schreiber S
Krysiak PS, Preiksaitis HG. Tachykinins Contribute to Nerve-Mediated Contractions in the Human Esophagus, 120:39
Kubota N. *See* Nakajima A
Kučera P. *See* Berčík P
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic Anion-Transporting Polypeptide B (OATP-B) and Its Functional Comparison With Three Other OATPs of Human Liver, 120: 525
Kullak-Ublick GA, Meier PJ. Organic Anion-Transporting Polypeptides: Expression Cloning and Functional Tests. Reply, 120:1888–c
Kumada H. *See* Ikeda K
Kumar R. *See* Mandal M
Kung H-J. *See* Grossmann J
Kuraishi A. *See* Maeyama H
Kuroki T. *See* Shiratori Y
Kurtz RC, Zhang Z-F. Gastric Cardia Cancer and Dietary Fiber, 120:568–e
Kuzhikandathil EV. *See* Finn AL
Kyokane T, Norimizu S, Taniai H, Yamaguchi T, Takeoka S, Tsuchida E, Naito M, Nimura Y, Ishimura Y, Suematsu M. Carbon Monoxide From Heme Catabolism in Endotoxic-Induced Rat Liver Protects Against Hepatobiliary Dysfunction, 120:1227

Lacy AM. *See* Bessa X
Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Gastric Distention Correlates With Activation of Multiple Cortical and Subcortical Regions, 120:369
Lafrenz M. *See* Wiese M
Lagergren J. *See* Terry P
Laharie D, Debeugny S, Peeters M, Van Gossum A, Gower-Rousseau C, Bélaïche J, Fiasse R, Dupas J-L, Lerebours E, Piotte S, Cortot A, Vermeire S, Grandbastien B, Colombel J-F. Inflammatory Bowel Disease in Spouses and Their Offspring, 120:816
Laine L. Approaches to Nonsteroidal Anti-Inflammatory Drug Use in the High-Risk Patient, 120:594
Lamireau T. *See* Cézard JP
Lammert F, Carey MC, Paigen B. Chromosomal Organization of Candidate Genes Involved in Cholesterol Gallstone Formation: A Murine Gallstone Map, 120:221–srr
Landers C. *See* Braun J
Landers CJ. *See* Taylor KD
Landmann L. *See* Kullak-Ublick GA
Lang HJ. *See* Grahammer F
Lanthorn T. *See* McRoberts JA
Lapidus A. *See* Askling J
Larkin GN
See Imperiale TF
See Lieberman DA
Larsen F. *See* Degen LP
LARusso NF
See Chen X-M
See Jaiswal M
Lassen A, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB
Helicobacter Eradication Versus Prompt Endoscopy for Dyspepsia, 120:1299–ss
Helicobacter Eradication Versus Prompt Endoscopy for Dyspepsia. Reply, 120: 1300–ss
Lau JYW. *See* Sung JJY
Laurent-Puig P. *See* Torrisani J
Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic Alterations Associated With Hepatocellular Carcinomas Define Distinct Pathways of Hepatocarcinogenesis, 120:1763
Layden JE, Layden TJ. How Can Mathematics Help Us Understand HCV?, 120:1546–e
Layden TJ. *See* Layden JE
Le Moine O. *See* Deviére J
Lechago J. *See* Younes M
Lecomte JM. *See* Cézard JP
Lee J-H. *See* Mulé F
Legarde AE. *See* Stern HS
Legoix P. *See* Laurent-Puig P
Lehy T. *See* Sobhani I
Lei J. *See* Abou-Saif A
Lemasters JJ. *See* Hatano E
Lembo T. *Fast Facts: Irritable Bowel Syndrome*. 120:1559–pmr
Lemmens L. *See* D'Haens G
León F, R-Pena R, Camarero C, Sánchez L, Eiras P, Amo A del, Bootello A, Roy G. Limitations of Anti-Guinea Pig Liver Transglutaminase IgA in Screening of Celiac Disease, 120: 586–c
Lepage AC. *See* Buzoni-Gatel D
Lerebours E. *See* Laharie D
Lerut A. *See* Sifrim D
Lesuffleur T. *See* Bras-Gonçalves RA
Levin TR. *See* Terdiman JP
Levine AD. *See* Grossmann J
Levine SA. *See* Chen X-M
Lewis JD. What Lies Beyond the View of the Sigmoidoscope? Comment, 120: 1052–ss
Lewis MC. *See* Lu TT
Ley C, Parsonnet J. *Helicobacter pylori* Infection and Gastric Cancer, 120: 324–c
Li L. *See* Repa JJ
Liang TJ. *See* Doo E
Lichtenstein GR
See Judge TA
See Yang Y-X
Lider O. *See* Chowers Y
Lieberman D. Colorectal Cancer: Not an Equal Opportunity Cancer, 120: 1043–e
Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G, Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. What Lies Beyond the View of the Sigmoidoscope?, 120:1051–ss
Liebisch G. *See* Drobnik W
Lien HC. *See* Huang YH
Lieser B. *See* Drobnik W
Lin CY
See Imperiale TF
See Lieberman DA
Lindenthal B. *See* Drobnik W
Lindor KD. *See* Angulo P
Liu C, Russell RM, Seitz HK, Wang X-D. Ethanol Enhances Retinoic Acid Metabolism Into Polar Metabolites in Rat Liver via Induction of Cytochrome P4502E1, 120:179
Liu X. *See* Merlin D
Liu X, Rusch NJ, Striessnig J, Sarna SK. Down-regulation of L-Type Calcium Channels in Inflamed Circular Smooth Muscle Cells of the Canine Colon, 120:480
Lobaccaro JA. *See* Repa JJ
Lochs H. *See* Schreiber S

Lockhart RR. *My Mom Has Hepatitis C*. 120:1056–pmr
Löfberg R. *See* Askling J
Loftus EV Jr. *See* Pardi DS
Loguercio C. *See* Marchesini G
Lohmann J. *See* Jeppesen PB
Lok A, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B: 2000-Summary of a Workshop, 120:1828–srr
Lorenzo-Zúñiga V. *See* Pérez-Páramo M
Lovat L. *See* Fitzgerald RC
Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwex J, Mangelsdorf DJ, Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi LB, Wilson JG, Lewis MC, Roth ME, Maloney PR, Wilson TM, Kliewer SA. Bile Acids Regulate Their Own Synthesis: The Nuclear Connection, 120:1557–ss
Lucas M. *See* Heuschen UA
Lügering N. *See* Dwinell MB
Luketic VA. *See* Sanyal AJ
Lund PK. *See* Williams KL
Lunel F. *See* Di Martino V
Luque T. *See* Pérez-Páramo M
Luster AD. Chemokines Regulate Lymphocyte Homing to the Intestinal Mucosa, 120:291–e
Lustig K. *See* Repa JJ
Lutzke LS. *See* Buttar NS
Lyons MR. *See* Cerda SR

Macarri G. *See* Benedetti A
Mackay IR. *See* Kita H
Madara JL
See Merlin D
See Shibahara T
Madonna P, Stefano V de, Coppola A, Cerbone AM, Minno G di. G20210A Prothrombin Gene Mutation and Other Trombophilic Polymorphisms in Patients With Portal or Hepatic Venous Thrombosis, 120:1059–c
Madsen JL. *See* Jeppesen PB
Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y, Katsuyama T. Familial Gastrointestinal Stromal Tumor With Hyperpigmentation: Association With a Germline Mutation of the *c-kit* Gene, 120:210–cr
Majima M. *See* Boku K
Makino S. *See* Asakawa A
Makishima M. *See* Lu TT
Malchow H. *See* Schreiber S
Mallet A. *See* Condat B
Mallonee DH. *See* Pandak WM
Maloney PR. *See* Lu TT
Mandal M, Olson DJ, Sharma T, Vadlamudi RK, Kumar R. Butyric Acid Induces Apoptosis by Up-regulating Bax Expression via Stimulation of the c-Jun N-Terminal Kinase/Activation Protein-1 Pathway in Human Colon Cancer Cells, 120:71
Mandal PK. *See* Takikawa Y
Mangelsdorf DJ
See Lu TT
See Repa JJ
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DUBois RN. Targeting Cyclooxygenase 2 and HER-2/*neu* Pathways Inhibits Colorectal Carcinoma Growth, 120:1713
Manning AM. *See* Hatano E
Manns MP
See Tillmann HL
See Wedemeyer H
Manns MP, Strassburg CP. Autoimmune Hepatitis: Clinical Challenges, 120:1502–srr
Mansouri A. *See* Degoul F
Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, Abbiati R. Factors Associated With Poor Health-Related Quality of Life of Patients With Cirrhosis, 120:170
Marcier B. *See* Chen J-M
Marcucci MT. *Positive Options for Crohn's Disease, Self-Help and Treatment*. 120:317–pmr
Mariadason JM, Velcich A, Wilson AJ, Augenlicht LH, Gibson PR. Resistance to Butyrate-Induced Cell Differentiation and Apoptosis During Spontaneous Caco-2 Cell Differentiation, 120:889
Marien G. *See* Vermeire S
Marmuse J-P. *See* Sobhani I
Marrogi AJ. *See* Hussain SP
Marshall JR. *See* Martínez ME
Martin SP. *See* Somogyi L
Martin V. *See* Buzoni-Gatel D
Martínez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma Characteristics as Risk Factors for Recurrence of Advanced Adenomas, 120:1077
Marvizón JCG. *See* McRoberts JA
Mason RP. *See* Wheeler MD
Matczak E. Human Papillomavirus Infection: An Emerging Problem in Anal and Other Squamous Cell Cancers, 120:1046–e
Matsuda Y. *See* Maeyama H
Matsuhashi N. *See* Nakajima A
Matsuno S. *See* Abe T
Matsuzaki H. *See* Schneider MB
Matsuzawa Y. *See* Miyazaki Y
Matthews JB
Pump Up the Volume: A Sound Policy?, 120:1075–ce
See Mun EC
Maurage C. *See* Cézard JP
Mayer EA. *See* McRoberts JA
McDermott CM, Abrahams TP, Partosoedarso E, Hyland N, Ekstrand J, Monroe M, Hornby PJ. Site of Action of GABAB Receptor for Vagal Motor Control of the Lower Esophageal Sphincter in Ferrets and Rats, 120:1749
McDonald JWD. *See* Feagan BG
McDonald TJ. *See* Abou-Saif A
McDonald V. *See* Pollok RCG
McKee DD. *See* Lu TT
McKinley MJ. *See* Slonim AE
McKinzie S. *See* Bouras EP
McLaren CE. *See* Theuer CP
McRoberts JA, Coutinho S, Marvizón JCG, Grady EF, Tognetto M, Sengupta JN, Ennes HS, Chaban VV, Amadesi S, Creminon C, Lanthorn T, Geppetti P, Bunnett NW, Mayer EA. Role of Peripheral *N*-Methyl-D-Aspartate (NMDA) Receptors in Visceral Nociception in Rats, 120:1737
Medina J. *See* Repa JJ
Mehal WZ, Azzaroli F, Crispe IN. Immunology of the Healthy Liver: Old Questions and New Insights, 120:250–srr
Meier PJ. *See* Kullak-Ublick GA
Meloche RM. *See* Buchan AMJ
Melpolder JC. *See* Farci P
Méndez-Sánchez N, Uribe M. Intestinal Motility and Bacterial Overgrowth in Patients With Gallstones, 120:1310–c
Meneveri R. *See* Barisani D
Mennechet FJD. *See* Buzoni-Gatel D
Mensink RG. *See* Wu Y
Meri S. *See* Rautemaa R
Merli M. *See* Marchesini G
Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, Liu X, Hediger MA, Madara JL. Colonic Epithelial hPepT1 Expression Occurs in Inflammatory Bowel Disease: Transport of Bacterial Peptides Influences Expression of MHC Class 1 Molecules, 120:1666
Metz A. *See* Schnell TG
Meyer D. *See* Veyradier A
Meyer M. *See* Cézard JP
Meyerhans A. *See* Schmidt W
Mignon M. *See* Sobhani I

Mihas AA. *See* Foody W
Miki H. *See* Nakajima A
Milano G. *See* Bras-Gonçalves RA
Milla PJ. Irritable Bowel Syndrome in Childhood, 120:287–e
Miller GA. *See* Terdiman JP
Miller LJ. *See* Coulie BJ
Millikan RE. *See* Takikawa Y
Minami S. *See* Maeyama H
Minno G di. *See* Madonna P
Minoshima S. *See* Ladabaum U
Mirin B. *See* Sobhani I
Mirshahi F. *See* Sanyal AJ
Mitic LL. *See* Rahner C
Miyazaki Y, Hiraoka S, Tsutsui S, Kitamura S, Shinomura Y, Matsuzawa Y. Epidermal Growth Factor Receptor Mediates Stress-Induced Expression of Its Ligands in Rat Gastric Epithelial Cells, 120:108
Miyoshi H. *See* Takikawa Y
Modi M. *See* Mulé F
Moffett J. *See* Brembeck FH
Moitinho E. *See* Escorsell A
Monges G. *See* Laurent-Puig P
Monroe M. *See* McDermott CM
Monsuur F. *See* Vermeire S
Montalto MC. *See* Wada K
Montembault S. *See* Veyradier A
Montosi G. *See* Zoller H
Moore LB. *See* Lu TT
Morali A. *See* Cézard JP
Moran AP. *See* Berstad AE
Mori H. *See* Maeyama H
Moriwaki H. *See* Okuno M
Moriya K. *See* Fujie H
Moriyama M. *See* Shiratori Y
Mortelmans L. *See* D'Haens G
Mortensen PB
See Jeppesen PB
See Jorgensen JR
Morton DH. *See* Salen G
Mulchandani R. *See* Nilsson H-O
Mulé F, Serio R. Increased Calcium Influx Is Responsible for the Sustained Mechanical Tone in Colon From Dystrophic *(mdx)* Mice, 120:1430
Mulholland MW. Progress in Understanding Acalculous Gallbladder Disease, 120:570–e
Müller MG. *See* Georgakoudi I
Mun EC, Blackburn GL, Matthews JB. Current Status of Medical and Surgical Therapy for Obesity, 120:669
Muñoz J
See Albillos A
See Pérez-Páramo M
Munoz SJ. *See* Farci P
Murashima N. *See* Ikeda K
Murata T. *See* Boku K
Musch MW. *See* Sugi K
Mustafi R. *See* Cerda SR
Mykoniatas A. *See* Singh VP

Nagai R. *See* Nakajima A
Nagashima M. *See* Hussain SP
Nagata T. *See* Asakawa A
Nagura H. *See* Abe T
Naito M. *See* Kyokane T
Nakagomi R. *See* Abe T
Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N. Endogenous PPARg Mediates Anti-inflammatory Activity in Murine Ischemia-Reperfusion Injury, 120:460
Nakajima N. *See* Nakajima A
Nakamura S. *See* Sugiyama T
Nakamura T
See Chiba M
See Sugiyama T
Nakata S. *See* Maeyama H
Narumiya S. *See* Boku K
Naveau S. *See* Veyradier A
Neave P. *See* Gibb DM
Neirynck S. *See* Steidler L
Nelson DB. *Helicobacter* Eradication Versus Prompt Endoscopy for Dyspepsia. Comment, 120:1300–ss
Nelson DJ. *See* Sugi K
Nelson V. *See* Hassard PV
Neumann AU. *See* Mulé F
Nevens F. *See* D'Haens G
Niero M. *See* Marchesini G
Nijima A. *See* Asakawa A
Nikolaus S. *See* Schreiber S
Niles JL. *See* Bitton A
Nilsson H-O, Mulchandani R, Tranberg K-G, Stenram U, Wadström T. *Helicobacter* Species Identified in Liver From Patients With Cholangiocarcinoma and Hepatocellular Carcinoma, 120:323–c
Nimura Y. *See* Kyokane T
Nishiguchi S. *See* Shiratori Y
Nishimura T. *See* Enomoto N
Nishio T. *See* Abe T
Nishioka NS. *See* Poneros JM
Nishiura T. *See* Enomoto N
Nitschke R. *See* Grahammer F
Norimizu S. *See* Kyokane T
Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R, Stephens H, Harrison P, Vaughan R, Donaldson P. Mapping MHC-Encoded Susceptibility and Resistance in Primary Sclerosing Cholangitis: The Role of MICA Polymorphism, 120:1475
Novak C. *See* Sandborn WJ
Novak S. *See* Wight NJ
Nunoki K. *See* Abe T
Nyrén O. *See* Terry P

Obara T. *See* Saitoh Y
Obermeier F. *See* Steidler L
Obert B. *See* Veyradier A
Obrist P. *See* Zoller H
Ochs A. *See* Rössle M
O'Connell S. *See* Schnell TG
Ocran K. *See* Rickes S
Oesen U. *See* Wiese M
Ohnishi S. *See* Nakajima A
Ohno T. *See* Boku K
Ohtani H. *See* Abe T
Okabe M. *See* Abe T
Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, Suzuki Y, Kojima S. Prevention of Rat Hepatic Fibrosis by the Protease Inhibitor, Camostat Mesilate, via Reduced Generation of Active TGF-β, 120:1784
Olek MJ. *See* Ascherio A
Olives JP. *See* Cézard JP
Olschewski M. *See* Rössle M
Olson DJ. *See* Mandal M
Omata M. *See* Shiratori Y
Ono K. *See* Abe T
Onogawa T. *See* Abe T
Opolon P. *See* Di Martino V
Oren R. *See* Blendis L
O'Riordan A, Shanahan F. p53 At The Crossroads of Colitis and Cancer, 120:1877–ss
O'Rourke K. *See* Stern HS
Ortiz-Berrocal J. *See* Pérez-Páramo M
Ortiz D, Arias IM. MDR3 Mutations: A Glimpse Into Pandora's Box and the Future of Canalicular Pathophysiology, 120:1549–e
Ota H. *See* Maeyama H
Otto B. *See* Feinle C
Oude Elferink RPJ. *See* Jacquemin E
Owyang C. *See* Ladabaum U
Oxford GS. *See* Finn AL

Paigen B. *See* Lammert F
Pandak WM, Bohdan P, Franklund C, Mallonee DH, Eggertsen G, Björkhem I, Vlahcevic ZR, Hylemon PB. Expression of Sterol 12α-Hydroxylase Alters Bile Acid Pool Composition in Primary Rat Hepatocytes and In Vivo, 120:1801
Pandrea I. *See* Bras-Gonçalves RA
Panella C. *See* Marchesini G
Panés J. *See* Sans M
Panés J, Piqué JM. Heparin Therapy for Ulcerative Colitis. Reply, 120:1307–c
Papa A, Danese S, Gasbarrini G, Gasbarrini

A. When Can Unfractionated Heparin Really Be Useful in the Treatment of Ulcerative Colitis?, 120:1306–c
Papo M. *See* Cabré E
Parafioriti A. *See* Barisani D
Pardi DS, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Treatment of Refractory Microscopic Colitis With Azathioprine and 6-Mercaptopurine, 120:1483–cr
Pardo A. *See* Pérez-Páramo M
Parés A. *See* Cabré E
Parkes M. *See* Vermeire S
Parkman HP. *See* Quigley EMM
Parsonnet J
See Arruda SMB de
See Ley C
Partosoedarso E. *See* McDermott CM
Pasricha PJ. *See* Saitoh Y
Passaro DJ. *See* Arruda SMB de
Paul M. *See* Jacquemin E
Paya CV. *See* Chen X-M
Peddis G. *See* Farci P
Pedersen FM. *See* Lassen A
Peeters M
See D'Haens G
See Laharie D
See Vermeire S
Peng F. *See* Degen LP
Penninckx F. *See* D'Haens G
Peppercorn MA. *See* Bitton A
Perelman LT. *See* Georgakoudi I
Pérez-Páramo M. *See* Albillos A
Pérez-Páramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J, Pardo A, Bartoli R, Lorenzo-Zúûiga V, Planas R, Viûado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull M. Prokinetics Reduce Bacterial Translocation in Cirrhosis: Will Sweeping the Gut Keep the Fluid Clean?, 120:314–ss
Perras H. *See* Stern HS
Perrillo RP. Acute Flares in Chronic Hepatitis B: The Natural and Unnatural History of an Immunologically Mediated Liver Disease, 120:1009–srr
Perucho M. *See* Yamamoto H
Pessayre D. *See* Degoul F
Pessione F. *See* Condat B
Pethig K. *See* Wedemeyer H
Petterson TM. *See* Buttar NS
Pfau PR, Sivak MV Jr. Endoscopic Diagnostics, 120:763
Pfützer R, Barmada MM, Whitcomb DC. Mutations of the Pancreatic Secretory Trypsin Inhibitor (PSTI) Gene in Idiopathic Chronic Pancreatitis. Reply, 120:1063–c
Pharaon I. *See* Cézard JP
Pietrangelo A. *See* Zoller H
Pigini P. *See* Benedetti A
Pilla JA, Zucker SD. Cesarian for C? Possibly. . . . Comment, 120:1556–ss
Pinieux G de. *See* Bras-Gonçalves RA
Piñol V. *See* Bessa X
Piotte S. *See* Laharie D
Piqué JM
See Bessa X
See Panés J
See Sans M
Pisacane PI. *See* Mann M
Pitchumoni CS. *See* Yadav D
Pizcueta P. *See* Sans M
Pizzagalli F. *See* Kullak-Ublick GA
Planas R
See Cabré E
See Pérez-Páramo M
Plevy SE. *See* Taylor KD
Pocard M. *See* Bras-Gonçalves RA
Pochapin MB. *Evidence Based Gastroenterology and Hepatology*, 120:1559–pmr
Podolsky DK
Editorial Transition, 120:1577–ce
Introduction, 120:593
See Camilleri M
See Iwakiri D
Poirson-Bichat F. *See* Bras-Gonçalves RA
Poliquin M. *See* Condat B
Pollok RCG, Farthing MJG, Bajaj-Elliott M, Sanderson IR, McDonald V. Interferon Gamma Induces Enterocyte Resistance Against Infection by the Intracellular Pathogen *Cryptosporidium parvum*, 120:99
Poneros JM, Brand S, Bouma BE, Tearney GJ, Compton CC, Nishioka NS. Diagnosis of Specialized Intestinal Metaplasia by Optical Coherence Tomography, 120:7
Pont JJ de. *See* D'Elios MM
Ponti F de. *See* Tonini M
Poon SK. *See* Huang YH
Popnikolov NK. *See* Saitoh Y
Porst H. *See* Wiese M
Portero F. *See* Pérez-Páramo M
Post JG. *See* Wu Y
Poujol A. *See* Cézard JP
Poulsen SS. *See* Jeppesen PB
Poupon M-F. *See* Bras-Gonçalves RA
Poupon R. *See* Rosmorduc O
Pour PM. *See* Schneider MB
Prats N. *See* Sans M
Preiksaitis HG. *See* Krysiak PS
Present DH
See Friedman S
See Sandborn WJ
Prete G del. *See* D'Elios MM
Price AB. *See* Salto-Tellez M
Price RR. *See* Lu TT
Puente E. *See* Torrisani J
Puolakkainen P. *See* Rautemaa R
Purcell RH. *See* Farci P

Qian T. *See* Hatano E
Quandalle P. *See* Guillem P
Quer JC. *See* Cabré E
Quere I. *See* Chen J-M
Quigley EMM, Hasler WL, Parkman HP. AGA Technical Review on Nausea and Vomiting, 120:263–aga

R-Pena R. *See* León F
Rades T. *See* Feinle C
Raedler A. *See* Schreiber S
Rafter J. *See* Glinghammar B
Raguenes O. *See* Chen J-M
Rahner C, Mitic LL, Anderson JM. Heterogeneity in Expression and Subcellular Localization of Claudins 2, 3, 4, and 5 in the Rat Liver, Pancreas, and Gut, 120:411
Raja K. *See* Hussain SP
Rajendran VM. *See* Geibel JP
Ransil B. *See* Bitton A
Ransohoff DF
See Imperiale TF
See Lieberman DA
Rautelin H. *See* Rautemaa R
Rautemaa R, Rautelin H, Puolakkainen P, Kokkola A, Kärkkäinen P, Meri S. Survival of *Helicobacter pylori* From Complement Lysis by Binding of GPI-Anchored Protectin (CD59), 120:470
Reeves C. *See* Terdiman JP
Reid ME. *See* Martínez ME
Reiser M. *See* Rössle M
Remaut E. *See* Steidler L
Repa JJ. *See* Lu TT
Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Manipulating Intestinal Cholesterol Absorption and Hepatic Cholesterol and Bile Acid Metabolism by Activation of Deorphanized Nuclear Receptors, 120:1054–ss
Riba J. *See* Pérez-Páramo M
Richmond BL, Boileau AC, Zheng S, Huggins KW, Granholm NA, Tso P, Hui DY. Compensatory Phospholipid Digestion Is Required for Normal Cholesterol Absorption in Pancreatic Phospholipase A_2 Gene-Targeted Mice, 120:1193
Rickes S, Ocran K, Wermke W. Image of the Month, 120:1579–im
Riddell RH. *See* Huizinga JD
Ridolfi F. *See* Benedetti A
Riecken E-O. *See* Schmidt W
Riehle DM. *See* Buttar NS
Rigotti A, Freeman MW. Manipulating

Intestinal Cholesterol Absorption and Hepatic Cholesterol and Bile Acid Metabolism by Activation of Deorphanized Nuclear Receptors, 120: 1055–ss
Rincon JP del, Thorner MO, Gaylinn BD. Motilin-Related Peptide and Ghrelin: Lessons From Molecular Techniques, Peptide Chemistry, and Receptor Biology, 120:587–c
Ring M. *See* Buchan AMJ
Rio M-C. *See* Tomasetto C
Ritter M. *See* Drobnik W
Rivard N. *See* Deschênes C
Rivera CA. *See* Enomoto N
Rizzo WB. *See* Sanyal AJ
Roberts P. *See* Takikawa Y
Robertson DAF. *See* Weaver SA
Rockey DC
Management of Gastric Varices. Comment, 120:1875–ss
Predicting the Outcome of Hepatitis C Virus Infection. Comment, 120:313–ss
Rodés J. *See* Escorsell A
Rodríguez-Iglesias P. *See* Cabré E
Rogge JD
See Imperiale TF
See Lieberman DA
Rolandi V. *See* Bergamaschi G
Romagnani S. *See* D'Elios MM
Ronco G. *See* Bras-Gonçalves RA
Rosenau J. *See* Tillmann HL
Rosenheim M. *See* Di Martino V
Rosmorduc O, Hermelin B, Poupon R
Differential HFE Allele Expression in Hemochromatosis Heterozygotes. Reply, 120:1308–c
MDR3 Gene Defect in Adults With Symptomatic Intrahepatic and Gallbladder Cholesterol Cholelithiasis, 120:1459
Ross C. *See* Huizinga JD
Rossi L. *See* Degen LP
Rössle M. *See* Gerbes A
Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl V, Deibert D, Olschewski M, Reiser M, Gerbes AL. Management of Refractory Ascites: Are Tips or Taps Tops?, 120:311–ss
Roth ME. *See* Lu TT
Roth WK. *See* Mulé F
Rotter JI. *See* Taylor KD
Roy G. *See* León F
Rubin PH. *See* Friedman S
Rubio C. *See* Bartkova J
Rusch NJ. *See* Liu X
Russell RM. *See* Liu C
Russo MP. *See* Weaver SA
Rust C. *See* Takikawa Y
Rustgi AK
Entangled in a Web(site)?, 120:1321–ce
Gastroenterology News, 120:3, 333, 785, 1073, 1319, 1575
See Brembeck FH
Rusyn I. *See* Wheeler MD
Rutgeerts P
See D'Haens G
See Vermeire S

Saab S, Han S. Successful Orthotopic Liver Transplantation. Reply, 120:1561–c
Sachar DB. *Inflammatory Bowel Disease: Clinical Diagnosis and Management*, 120:1057–pmr
Saeki T. *See* Boku K
Saigenji K. *See* Boku K
Saitoh S. *See* Ikeda K
Saitoh Y, West AB, Popnikolov NK, Gatalica Z, Watari J, Obara T, Kohgo Y, Waxman I, Pasricha PJ. Prevalence and Distinctive Biologic Features of Flat Colorectal Adenomas in a North American Population, 120:1657
Sakisaka S. *See* Harada M
Salas A. *See* Sans M
Salen G, Knisely AS, Shneider B, Bull L, Morton DH. Abnormal Hepatic Sinusoidal Bile Acid Transport: New Insights Into the Pathogenesis of Cholestasis? Reply, 120:322–c
Salerno F. *See* Marchesini G
Saló J. *See* Bessa X
Salto-Tellez M, Davidson RD, Price AB. Image of the Month, 120:1076–im
Saluja AK. *See* Singh VP
Sampliner R. *See* Martínez ME
Samulski RJ. *See* Wheeler MD
Sánchez L. *See* León F
Sánchez-Lombraña JL. *See* Cabré E
Sandborn WJ. *See* Pardi DS
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan CN. An Engineered Human Antibody to TNF (CDP571) for Active Crohn's Disease, 120:1330
Sanders KM. Organization of Intestinal Pacemakers, 120:319–c
Sanderson IR. *See* Pollok RCG
Sandler RS. Presentation of the Julius M. Friedenwald Medal to Don W. Powell, M.D., 120:1854–aga
Sang Q. *See* Hirano I
Sans M, Salas A, Soriano A, Prats N, Gironella M, Pizcueta P, Elena M, Anderson DC, Piqué JM, Panés J. Differential Role of Selections in Experimental Colitis, 120:1162
Santos J. *See* Pérez-Páramo M
Santos M. *See* Pérez-Páramo M
Sanyal AJ. Octreotide and Its Effects on Portal Circulation, 120:303–e
Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities, 120: 1183
Sarles J. *See* Cézard JP
Sarna SK. *See* Liu X
Sartor RB
See Veltkamp C
See Williams KL
Sata M
See Harada M
See Shiratori Y
Sato E. *See* Abe T
Satsangi J
See Norris S
See Vermeire S
Saubermann LJ. *See* Nakajima A
Sawa A. *See* Watkins CC
Scaglione-Sewell B. *See* Cerda SR
Schäfer M. *See* Schmidt W
Schaffalitzky de Muckadell OB. *See* Lassen A
Scheffer GL. *See* Jacquemin E
Schemmer P. *See* Enomoto N
Schmidt W, Wahnschaffe U, Schäfer M, Zippel T, Arvand M, Meyerhans A, Riecken E-O, Ullrich R. Rapid Increase of Mucosal CD4 T Cells Followed by Clearance of Intestinal Cryptosporidiosis in an AIDS Patient Receiving Highly Active Antiretroviral Therapy, 120:984–cr
Schmitt A. *See* Terdiman JP
Schmitt-Gräff A. *See* Grahammer F
Schmitt M. *See* Fischer R
Schmitz G. *See* Drobnik W
Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding X-Z, Adrian TE, Pour PM. Prevention of Pancreatic Cancer Induction in Hamsters by Metformin, 120:1263
Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, Seidel UJ, Sonnenberg A. Long-term Nonsurgical Management of Barrett's Esophagus With High-Grade Dysplasia, 120: 1607
Schölmerich J. *See* Grossmann J
Schoonjans K. *See* Lu TT
Schor H. *See* Chowers Y
Schotte L. *See* Steidler L
Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G. Absence of Efficacy of Subcutaneous Antisense ICAM-1 Treatment of

Chronic Active Crohn's Disease, 120: 1339
Schrump DS. *See* Abou-Saif A
Schubert ML. *See* Foody W
Schuppan D. Limitations of Anti-Guinea Pig Liver Transglutaminase IgA in Screening of Celiac Disease. Reply, 120:587–c
Schwartzman JD. *See* Buzoni-Gatel D
Sebo TJ. *See* Buttar NS
Seidel UJ. *See* Schnell TG
Seitz HK. *See* Liu C
Seki M. *See* Abe T
Selinka H-C. *See* Sotlar K
Sengupta JN. *See* McRoberts JA
Serfas K. *See* Stern HS
Serio R. *See* Mulé F
Serrano Y. *See* Degen LP
Seto M. *See* Sugiyama T
Severs N. *See* Deviére J
Shah S
See Bitton A
See Kojic EM
Shan B. *See* Repa JJ
Shanahan F
Inflammatory Bowel Disease: Immunodiagnostics, Immunotherapeutics, and Ecotherapeutics, 120:622
Turbo Probiotics for IBF. Comment, 120:1297–ss
See O'Riordan A
Shannon B. *See* Elsaleh H
Shao J. *See* Mann M
Shapiro RA. *See* Jaiswal M
Sharma T. *See* Mandal M
Sheng H. *See* Mann M
Sherman NJ. *See* Teitelbaum DH
Shi G. *See* Hirano I
Shibahara T, Wilcox JN, Couse T, Madara JL. Characterization of Epithelial Chemoattractants for Human Intestinal Intraepithelial Lymphocytes, 120:60
Shields PG. *See* Hussain SP
Shiffman ML. *See* Sanyal AJ
Shiiba K. *See* Abe T
Shimoda A. *See* Farci P
Shimosegawa T. *See* Abe T
Shinomura Y. *See* Miyazaki Y
Shintani Y. *See* Fujie H
Shiratori Y, Imazeki F, Moriyama M, Yang M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Is Hepatic Fibrosis Reversible With Therapy in Hepatitis C?, 120:579–ss
Shirota Y. *See* Honda M
Shneider B. *See* Salen G
Shojamanesh H. *See* Abou-Saif A
Si-Tahar M. *See* Merlin D
Siegel R. *See* Takikawa Y
Siegerstetter V. *See* Rössle M
Sierro F. *See* Debard N
Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, Janssens J. Acid, Nonacid, and Gas Reflux in Patients With Gastroesophageal Reflux Disease During Ambulatory 24-Hour pH-Impedance Recordings, 120:1588
Sijmons RH. *See* Wu Y
Silny J. *See* Sifrim D
Singh VP, Saluja AK, Bhagat L, Hietaranta AJ, Song A, Mykoniatas A, Van Acker GJD, Steer ML. Serine Protease Inhibitor Causes F-Actin Redistribution and Inhibition of Calcium-Mediated Secretion in Pancreatic Acini, 120:1818
Sircar K. *See* Huizinga JD
Sitaraman SV. *See* Merlin D
Sivak MV Jr. *See* Pfau PR
Skandalis N. *See* Archimandritis A
Sleisenger MH. *See* Terdiman JP
Slezak P. *See* Bartkova J
Sliwkowski MX. *See* Mann M
Slonim AE, Bulone L, Damore MB, Golberg T, Wingertzahn MA, McKinley MJ. Novel Medical Therapies for Crohn's Disease: Is There Room for Growth?, 120:308–ss
Sly WS. *See* Griffiths WJH
Smith PD. *See* Janoff EN
Snyder SH. *See* Watkins CC
Sobhani I, Vuagnat A, Walker F, Vissuzaine C, Mirin B, Hervatin F, Marmuse J-P, Crémieux A-C, Carbon C, Henin D, Lehy T, Mignon M. Prevalence of High-Grade Dysplasia and Cancer in the Anal Canal in Human Papillomavirus-Infected Individuals, 120:857
Sodeyama H. *See* Maeyama H
Sokal EM. *See* Jacquemin E
Somasundaram S. Pathogenesis of Diclofenac Enteropathy, 120:1885–c
Somogyi L, Martin SP, Venkatesan T, Ulrich CD II. Recurrent Acute Pancreatitis: An Algorithmic Approach to Identification and Elimination of Inciting Factors, 120: 708
Song A. *See* Singh VP
Sonnenberg A. *See* Schnell TG
Sontag SJ. *See* Schnell TG
Soriano A. *See* Sans M
Sorrentino D, DeBiase F. Organic Anion-Transporting Polypeptides: Expression Cloning and Functional Tests, 120: 1887–c
Sotlar K, Köveker G, Aepinus C, Selinka H-C, Kandolf R, Bültmann B. Human Papillomavirus Type 16-Associated Primary Squamous Cell Carcinoma of the Rectum, 120: 988–cr
Southwell BR, Furness JB. Immunohistochemical Demonstration of the NK_1 Tachykinin Receptor on Muscle and Epithelia in Guinea Pig Intestine, 120:1140
Spechler SJ. Disputing Dysplasia, 120:1864–e
Spelta V. *See* Tonini M
Splinter PL. *See* Chen X-M
Squires PE. *See* Buchan AMJ
Srinivasan R. *See* Vela MF
Stahl GL. *See* Wada K
Standop J. *See* Schneider MB
Stanger B. *Development of the Gastrointestinal Tract*, 120:1883–pmr
Stanghellini V. *See* Tonini M
Steer ML. *See* Singh VP
Stefano V de. *See* Madonna P
Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Turbo Probiotics for IBF, 120:1298–ss
Steinmann G. *See* Schreiber S
Stenram U. *See* Nilsson H-O
Stephens H. *See* Norris S
Sterling RK. *See* Sanyal AJ
Stern HS, Viertelhausen S, Hunter AGW, O'Rourke K, Cappelli M, Perras H, Serfas K, Blumenthall A, Dewar D, Baumann E, Legarde AE. *APC* I1307K Increases Risk of Transition From Polyp to Colorectal Carcinoma in Ashkenazi Jews, 120:392
Stern J. *See* Heuschen UA
Sternini C. *See* Tonini M
Stevens AC. *See* Bitton A
Stieger B. *See* Kullak-Ublick GA
Stone CD, Beejay U, Wolfe MM. Image of the Month, 120:6–im
Strain AJ. *See* Crosby HA
Strassburg CP. *See* Manns MP
Strazzera A. *See* Farci P
Striessnig J. *See* Liu X
Sturm E. *See* Jacquemin E
Suematsu M. *See* Kyokane T
Suganuma T. *See* Harada M
Sugi K, Musch MW, Field M, Chang EB. Inhibition of Na^+, K^+-ATPase by Interferon γ Down-regulates Intestinal Epithelial Transport and Barrier Function, 120:1393
Sugi K, Musch MW, Nelson DJ, Chang EB. Oxidants Potentiate Ca^{2+}- and cAMP-Stimulated Cl^- Secretion in Intestinal Epithelial T84 Cells, 120:89
Sugita J. *See* Abe T
Sugiyama T. *See* Harada M

Sugiyama T, Asaka M, Nakamura T, Nakamura S, Yonezumi M, Seto M. API2-MALT1 Chimeric Transcript is a Predictive Marker for the Responsiveness of *H. pylori* Eradication Treatment in Low-Grade Gastric MALT Lymphoma, 120:1884–c
Sun D. *See* Georgakoudi I
Sung JJY, Lau JYW, Yu LM, To KF. *Helicobacter pylori* Infection and Gastric Cancer. Reply, 120:325–c
Susini C. *See* Torrisani J
Sutherland LR. *See* Sandborn WJ
Sutton A. *See* Degoul F
Sutton CL. *See* Braun J
Suzuki F. *See* Ikeda K
Suzuki M. *See* Abe T
Suzuki T. *See* Abe T
Suzuki Y
See Ikeda K
See Okuno M
Svegliati-Baroni G. *See* Benedetti A
Swenberg JA. *See* Hussain SP
Szabo I. *See* Tarnawski AS

Tack J. *See* Sifrim D
Takeoka S. *See* Kyokane T
Takikawa Y, Miyoshi H, Rust C, Roberts P, Siegel R, Mandal PK, Millikan RE, Gores GJ. The Bile Acid-Activated Phosphatidylinositol 3-Kinase Pathway Inhibits Fas Apoptosis Upstream of Bid in Rodent Hepatocytes, 120:1810
Tal R. *See* Chowers Y
Taminiau JAJM. *See* van Ginkel R
Tanemoto M. *See* Abe T
Taniai H. *See* Kyokane T
Taniguchi E. *See* Harada M
Targan CN. *See* Sandborn WJ
Targan SR
See Braun J
See Taylor KD
Tarnawski AS, Szabo I. Apoptosis-Programmed Cell Death and Its Relevance to Gastrointestinal Epithelium: Survival Signal From the Matrix, 120:294–e
Tatum RP. *See* Hirano I
Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA Pattern and LTA Haplotype Relationship to Clinical Responses to Anti-TNF Antibody Treatment in Crohn's Disease, 120:1347
Taylor TH. *See* Theuer CP
Tearney GJ. *See* Poneros JM
Teitelbaum DH. Single-Stage Operations for Hirschsprung's Disease: Pushing the Envelope. Reply, 120:1302–ss
Teitelbaum DH, Cilley RE, Sherman NJ. Single-Stage Operations for Hirschsprung's Disease: Pushing the Envelope, 120:1300–ss
Terada K. *See* Harada M
Terauchi Y. *See* Nakajima A
Terdiman JP, Gum JR Jr, Conrad PG, Miller GA, Weinberg V, Crawley SC, Levin TR, Reeves C, Schmitt A, Hepburn M, Sleisenger MH, Kim YS. Efficient Detection of Hereditary Nonpolyposis Colorectal Cancer Gene Carriers by Screening for Tumor Microsatellite Instability Before Germline Genetic Testing, 120:21
Terhorst C. *See* Veltkamp C
Terry P, Lagergren J, Ye W, Wolk A, Nyrén O. Inverse Association Between Intake of Cereal Fiber and Risk of Gastric Cardia Cancer, 120:387
Theuer CP, Wagner JL, Taylor TH, Brewster WR, Tran D, McLaren CE, Anton-Culver H. Racial and Ethnic Colorectal Cancer Patterns Affect the Cost-effectiveness of Colorectal Cancer Screening in the United States, 120:848
Theurl I. *See* Zoller H
Thomas G. *See* Laurent-Puig P
Thomas GA. *See* Georgakoudi I
Thomas LA. *See* Dowling RH
Thomas R. *See* Friedel D
Thomassen LH. *See* Bartkova J
Thomforde G. *See* Bouras EP
Thorner MO. *See* Rincon JP del
Thulesen J. *See* Jeppesen PB
Thullberg M. *See* Bartkova J
Thurman RG
See Enomoto N
See Wheeler MD
Tietz PS. *See* Chen X-M
Tillmann HL, Rosenau J, Tratwein C, Boeker KHW, Manns MP. Successful Orthotopic Liver Transplantation, 120:1561–c
To KF. *See* Sung JJY
Tofteng F. *See* Jeppesen PB
Tognetto M. *See* McRoberts JA
Tokui T. *See* Abe T
Tomasetto C, Rio M-C. Identification of Motilin-Related Peptide. Reply, 120:589–c
Tomlinson I, Houlston R. Is EXO1 a Colon Cancer Predisposition Gene?, 120:1860–e
Tonini M, Spelta V, Ponti F de, Giorgio R de, D'Agostino G, Stanghellini V, Corinaldesi R, Sternini C, Crema F. Tachykinin-Dependent and -Independent Components of Peristalsis in the Guinea Pig Isolated Distal Colon, 120:938
Tonkonogy SL. *See* Veltkamp C
Tonnini C. *See* Benedetti A
Torrisani J, Bouisson M, Puente E, Capellá G, Laurent-Puig P, Berger A, Vaysse N, Susini C, Buscail L. Transcription of SST2 Somatostatin Receptor Gene in Human Pancreatic Cancer Cells Is Altered by Single Nucleotide Promoter Polymorphism, 120:200
Tran D. *See* Theuer CP
Tranberg K-G. *See* Nilsson H-O
Tratwein C. *See* Tillmann HL
Trauner M, Fickert P, Zollner G. Abnormal Hepatic Sinusoidal Bile Acid Transport: New Insights Into the Pathogenesis of Cholestasis?, 120:321–c
Treinen-Moslen M, West AB, Atchison CR. Why the Mesenteric Margin? Reply, 120:1886–c
Tremaine WJ. *See* Pardi DS
Trépo C. *See* Bain C
Triboulet J-P. *See* Guillem P
Tsai M-H. *See* Wiest R
Tso P. *See* Richmond BL
Tsubota A. *See* Ikeda K
Tsuchida E. *See* Kyokane T
Tsutsui S. *See* Miyazaki Y
Turley SD. *See* Repa JJ
Tutuian R. *See* Vela MF
Tytgat GNJ. GERD Remains an Intriguing Enigma, 120:787–ce

Ueno N. *See* Asakawa A
Ullrich R. *See* Schmidt W
Ulrich A. *See* Schneider MB
Ulrich CD II. *See* Somogyi L
Unno M. *See* Abe T
Uribe M. *See* Méndez-Sánchez N

Vadlamudi RK. *See* Mandal M
Vaillant JM. *See* Cézard JP
Valla D
See Condat B
See Degoul F
Vallance B. *See* Barbara G
Van Acker F. *See* D'Haens G
Van Acker GJD. *See* Singh VP
Van Dam J. *See* Georgakoudi I
Van de Water J. *See* Kita H
van der Sluis T. *See* Wu Y
van der Zee AGJ. *See* Wu Y
van Ginkel R, Voskuijl WP, Benninga MA, Taminiau JAJM, Boeckxstaens GE. Alterations in Rectal Sensitivity and Motility in Childhood Irritable Bowel Syndrome, 120:31
Van Gossum A. *See* Laharie D
Van Laethem J-L. *See* Deviére J
Vandenbroucke-Grauls CM. *See* D'Elios MM
Vandeputte L. *See* D'Haens G

Vasiliauskas EA. *See* Hassard PV
Vaughan R. *See* Norris S
Vaysse N. *See* Torrisani J
Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous Intraesophageal Impedance and pH Measurement of Acid and Nonacid Gastroesophageal Reflux: Effect of Omeprazole, 120: 1599
Velcich A. *See* Mariadason JM
Veltkamp C, Tonkonogy SL, Jong YP de, Albright C, Grenther WB, Balish E, Terhorst C, Sartor RB. Continuous Stimulation by Normal Luminal Bacteria Is Essential for the Development and Perpetuation of Colitis in Tge26 Mice, 120:900
Venkatesan T. *See* Somogyi L
Verlind E. *See* Wu Y
Vermeire S
See D'Haens G
See Laharie D
Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative Study of ASCA (Anti-*Saccharomyces cerevisiae* Antibody) Assays in Inflammatory Bowel Disease, 120:827
Vermeire S, Satsangi J, Peeters M, Parkes M, Jewell DP, Vlietinck R, Rutgeerts P. Evidence for Inflammatory Bowel Disease of a Susceptibility Locus on the X Chromosome, 120:834
Veyradier A, Balian A, Wolf M, Giraud V, Montembault S, Obert B, Dagher I, Chaput J-C, Meyer D, Naveau S. Abnormal von Willebrand Factor in Bleeding Angiodysplasias of the Digestive Tract, 120:346
Vézina A. *See* Deschênes C
Viertelhausen S. *See* Stern HS
Villa P. *See* Bras-Gonçalves RA
Vissuzaine C. *See* Sobhani I
Viúdo B. *See* Pérez-Páramo M
Vlahcevic ZR. *See* Pandak WM
Vlietinck R. *See* Vermeire S
Vogel W. *See* Zoller H
Von Bergmann K. *See* Drobnik W
Voskuijl WP. *See* van Ginkel R
Vuagnat A. *See* Sobhani I

Wada K. *See* Nakajima A
Wada K, Montalto MC, Stahl GL. Inhibition of Complement C5 Reduces Local and Remote Organ Injury After Intestinal Ischemia/Reperfusion in the Rat, 120:126
Wada S. *See* Maeyama H
Wadström T. *See* Nilsson H-O
Wagner DR
See Imperiale TF
See Lieberman DA
Wagner JL. *See* Theuer CP
Wahnschaffe U. *See* Schmidt W
Walker AM. *See* Ascherio A
Walker F. *See* Sobhani I
Wallace MB. *See* Georgakoudi I
Wang K. Photodynamic Therapy and Genetic Abnormalities, 120:1065–c
Wang KK. *See* Buttar NS
Wang Q, Wang X, Hernandez A, Kim S, Evers BM. Inhibition of the Phosphatidylinositol 3-Kinase Pathway Contributes to HT29 and Caco-2 Intestinal Cell Differentiation, 120: 1381
Wang TC. *See* Brembeck FH
Wang X. *See* Wang Q
Wang X-D. *See* Liu C
Ward SG. *See* Weaver SA
Warner BW
GLP-2 as Therapy for the Short-Bowel Syndrome, 120:1041–e
Single-Stage Operations for Hirschsprung's Disease: Pushing the Envelope. Comment, 120:1301–ss
Warth R. *See* Grahammer F
Wasmuth HE. *See* Brandenburg VM
Watanabe M. *See* Maeyama H
Watari J. *See* Saitoh Y
Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, Snyder SH, Ferris CD. Are Things Looking Up for the Treatment of Gastroparesis? Sildenafil in Animal Models of Diabetic Gastropathy, 120:576–ss
Watson MA. *See* Lu TT
Waxman I. *See* Saitoh Y
Waxman IF. *See* Abou-Saif A
Weaver SA, Russo MP, Wright KL, Kolios G, Jobin C, Robertson DAF, Ward SG. Regulatory Role of Phosphatidylinositol 3-Kinase on TNF-α-Induced Cyclooxygenase 2 Expression in Colonic Epithelial Cells, 120:1117
Weber TC. *See* Drobnik W
Wedemeyer H, Pethig K, Manns MP, Böker KHW. Hepatitis B Infection in Heart Transplant Recipients, 120: 1311–c
Wei B. *See* Braun J
Weinberg V. *See* Terdiman JP
Weisiger RA. Carbon Monoxide and Sepsis: Is a Toxic Gas Good For Your Liver?, 120:1288–e
Weiss DG. *See* Lieberman DA
Weiss G. *See* Zoller H
Wermke W. *See* Rickes S
West AB
See Saitoh Y
See Treinen-Moslen M
Whately-Smith C. *See* Cézard JP
Wheeler MD, Kono H, Yin M, Rusyn I, Froh M, Connor HD, Mason RP, Samulski RJ, Thurman RG. Delivery of the Cu/Zn-Superoxide Dismutase Gene With Adenovirus Reduces Early Alcohol-Induced Liver Injury in Rats, 120:1241
Whitcomb DC
See Etemad B
See Pfützer R
Wiese M. *See* Berr F
Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. The Road Not Taken, 120: 1878–ss
Wiest R, Tsai M-H, Groszmann RJ. ctreotide Potentiates PKC-Dependent Vasoconstrictors in Portal-Hypertensive and Control Rats, 120:975
Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ. Rofecoxib, a COX-2 Inhibitor, Does Not Inhibit Human Gastric Mucosal Prostaglandin Production, 120:867
Wilcox JN. *See* Shibahara T
Wild G. *See* Bitton A
Williams CS. *See* Mann M
Williams I. *See* Merlin D
Williams KL, Fuller CR, Dieleman LA, DACosta CM, Haldeman KM, Sartor RB, Lund PK. Enhanced Survival and Mucosal Repair After Dextran Sodium Sulfate-Induced Colitis in Transgenic Mice That Overexpress Growth Hormone, 120:925
Wilson AJ. *See* Mariadason JM
Wilson JG. *See* Lu TT
Wilson TM. *See* Lu TT
Wingertzahn MA. *See* Slonim AE
Witt H, Hennies HC, Becker M. *SPINK1* Mutations in Chronic Pancreatitis, 120:1060–c
Wittekindt OH. *See* Grahammer F
Wolf DC. *See* Sandborn WJ
Wolf M. *See* Veyradier A
Wolfe MM. *See* Stone CD
Wolk A. *See* Terry P
Wong F. *See* Benjaminov F
Wong P. *See* Wight NJ
Wright KL. *See* Weaver SA
Wu CY. *See* Huang YH
Wu Y, Berends MJW, Post JG, Mensink RG, Verlind E, van der Sluis T, Kempinga C, Sijmons RH, van der Zee AGJ, Hollema H, Kleinbeuker JH, Buys CHCM, Hofstra RMW.

Germline Mutations of *EXO1* Gene in Patients With Hereditary Nonpolyposis Colorectal Cancer (HNPCC) and Atypical HNPCC Forms, 120:1580–rc

Xiao Z-L. *See* Amaral J
Xin Z. *See* Sifrim D

Yadav D, Hughes J, Pitchumoni CS. Image of the Month, 120:788–im
Yamada G. *See* Shiratori Y
Yamada T. *See* Boland CR
Yamaguchi T. *See* Kyokane T
Yamamoto H, Yamashita K, Perucho M. Somatic Mutation of the β_2-Microglobulin Gene Associates With Unfavorable Prognosis in Gastrointestinal Cancer of the Microsatellite Mutator Phenotype, 120:1565–c
Yamane A. *See* Braun J
Yamashina S. *See* Enomoto N
Yamashita K. *See* Yamamoto H
Yang H. *See* Taylor KD
Yang M. *See* Shiratori Y
Yang S. *See* Arruda SMB de
Yang SS. *See* Huang YH
Yang Y-X, Lichtenstein GR. Methotrexate for the Maintenance of Remission in Crohn's Disease. Comment, 120:1554–ss
Ye W. *See* Terry P
Yeh HZ. *See* Huang YH
Yeh H-Z, Huang Y-H. Management of Gastric Varices. Reply, 120:1876–ss
Yin M. *See* Wheeler MD
Yokosuka O. *See* Shiratori Y
Yonezumi M. *See* Sugiyama T
Yoshida H. *See* Shiratori Y
Yotsuyanagi H. *See* Fujie H
Younes M, Lechago J, Ertan A. Photodynamic Therapy and Genetic Abnormalities, 120:1065–c
Younossi ZM. Chronic Liver Disease and Health-Related Quality of Life, 120:305–e
Yu LM. *See* Sung JJY
Yu P. *See* Amaral J
Yuzuriha H. *See* Asakawa A

Zarski J-P. *See* Bain C
Zeitoun G. *See* Condat B
Zeuzem S, Herrmann E, Lee J-H, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral Kinetics in Patients With Chronic Hepatitis C Treated With Standard or Peginterferon α2a, 120:1438
Zhang Q. *See* Georgakoudi I
Zhang SM. *See* Ascherio A
Zhang Z-F. *See* Kurtz RC
Zheng S. *See* Richmond BL
Zhong Z. *See* Enomoto N
Zinsmeister AR. *See* Bouras EP
Zippel T. *See* Schmidt W
Zoller H, Koch RO, Theurl I, Obrist P, Pietrangelo A, Montosi G, Haile DJ, Vogel W, Weiss G. Expression of the Duodenal Iron Transporters Divalent-Metal Transporter 1 and Ferroportin 1 in Iron Deficiency and Iron Overload, 120:1412
Zollner G. *See* Trauner M
Zoulim F. *See* Bain C
Zucker SD
  The Hepatitis B Vaccine: Sorting Through the B.S. About M.S.. Comment, 120:1881–ss
  Management of Refractory Ascites: Are Tips or Taps Tops? Comment, 120:311–ss
  See Pilla JA
Zucman-Rossi J. *See* Laurent-Puig P

SUBJECT INDEX TO VOLUME 120

Abacavir, GI toxicity and GI-associated drug interactions of, 120:607
ABT 378, GI toxicity and GI-associated drug interactions of, 120:607
Achalasia, diagnosis of, esophageal manometry for, 120:783–tmig, 120:789
Acquired immunodeficiency syndrome (AIDS). *See* HIV-infected (AIDS) patients; Human immunodeficiency virus (HIV-1)
Activation protein 1 (AP-1), and butyric acid-induced apoptosis in colon cancer cells, 120:71
Adaptive cytoprotection, in gastric mucosa, PGI_2 and CGRP in, 120:134
Adefovir dipivoxil
GI toxicity and GI-associated drug interactions of, 120:607
therapy with, for hepatitis B, 120:1828–srr
Adenomas
characteristics of, and risk of recurrence, 120:1071–tmig, 120:1077
colonic
exophytic, aberrant expression of G1-phase cell cycle regulators in, 120:1680
flat, aberrant expression of G1-phase cell cycle regulators in, 120:1680
colorectal, flat, prevalence and biologic features of, in North American population, 120:1657
Agenerase. *See* Amprenavir
Alcohol. *See* Ethanol
Alcoholic steatosis, Kupffer cell in (rat), 120:581–ss
Alosetron
adverse effects and side effects of, 120:557–cr, 120:652
ischemic colitis caused by, 120:557–cr
therapy with, in irritable bowel syndrome, 120:652
Alport syndrome, pathology of, 120:216–cr
Alternative medicine, in treatment of irritable bowel syndrome, 120:652
American Gastroenterological Association
and HCFA policy effects on gastroenterologists and Medicare patients, 120:3–gn
medical position statement
on celiac sprue, 120:1522
on guidelines for evaluation of food allergies, 120:1023
on nausea and vomiting, 120:261
new president—Jon I. Isenberg, M.D., 120:1518
goals of, 120:786–gn
presentation of the Julius M. Friedenwald Medal to Don W. Powell, M.D., 120:1854
technical review
on celiac sprue, 120:1526
on evaluation of food allergy in gastrointestinal disorders, 120:1026
on nausea and vomiting, 120:263
Amprenavir, GI toxicity and GI-associated drug interactions of, 120:607
Anal canal, cancer of, risk of, HPV and, 120:784–tmig, 120:857, 120:1046–e
Anal fistula, in Crohn's disease, initial medical management for, cost-utility of, 120:1640
Anemia, duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404
Angiodysplasia, bleeding, of gastrointestinal tract, abnormal von Willebrand factor in, 120:346
Anticoagulant therapy
for mesenteric vein thrombosis, 120:578–ss
for portal vein thrombosis, 120:490, 120:578–ss
Antidepressants, in treatment of irritable bowel syndrome, 120:652
Antidiarrheal agents, in treatment of irritable bowel syndrome, 120:652
Antiemetic agents, for nausea and vomiting, 120:263–aga
Antimitochondrial antibody, in liver disease, 120:239–srr
Antineutrophil cytoplasmic antibody (ANCA), and LTA haplotype, and responses to infliximab in Crohn's disease, 120:1347
Antinuclear antibodies, in liver disease, 120:239–srr
Antiretroviral therapy, for HIV-1 infection
adverse effects and side effects of, 120:607
efficacy of, 120:607
Antisense ICAM-1, in treatment of chronic active Crohn's disease, 120:1317–tmig, 120:1339
***APC* gene,** I1307K mutation, and increased risk of transition from polyp to colorectal carcinoma in Ashkenazi Jews, 120:331–tmig, 120:392
Apoptosis
butyric acid-induced, JNK/AP1 pathway in, 120:71
of $CD8^+$ T cells, in liver, 120:250–srr
in colon cancer cells, butyric acid–induced, 120:71
resistance to, during spontaneous Caco-2 cell differentiation, 120:889
in epithelial cells
prevention of, *Cryptosporidium parvum*-activated factor κB and, 120:1774
signal transduction during, 120:79, 120:294–e
in hepatic stellate cells
peripheral-type benzodiazepine receptor expression and, 120:1212, 120:1285–e
in tissue injury, 120:1212, 120:1285–e
in hepatocytes
Fas-mediated, inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810
TNF-α- and Fas-mediated, NF-κB stimulation of inducible nitric oxide synthase and (mouse), 120:1251
PKC-δ and, in Caco-2 cells, 120:1700, 120:1868–e
Appendectomy, laparoscopic, in patients with refractory ulcerative colitis, 120:1562–c
Appetite, regulation of, ghrelin in, 120:337–rc
Arteriovenous malformations, hepatic, 120:1579–im

KEY TO ABBREVIATIONS

aga—American Gastroenterological Association
c—Correspondence
ce—Comment From the Editors
cr—Case Reports
gn—Gastroenterology News
e—Editorials
im—Image of the Month
pmr—Print and Media Reviews
rc—Rapid Communications
ss—Selected Summaries
srr—Special Reports and Reviews
tmig—This Month in Gastroenterology
vidd—Viewpoints in Digestive

ASCA (anti-*Saccharomyces cerevisiae* antibody), assays, in inflammatory bowel disease, comparative study of, 120:827
Aschoff, Carl Albert Ludwig, 120:1598
Ascites
current management of, 120:726
new-onset, treatment of, 120:726
refractory, management of, 120:311–ss, 120:726
Ashkenazi Jews, *APC* I1307K mutation in, and increased risk of colorectal cancer, 120:331–tmig, 120:392
ATP-binding cassette transporter A1 (ABCA1), and cholesterol metabolism, 120:1203
ATP7B (Wilson disease) protein, mutants
localization of, 120:784–tmig, 120:967
properties of, 120:784–tmig, 120:967
Autoantibodies
in autoimmune hepatitis, 120:1502–srr
in liver disease, 120:239–srr
Autoimmune gastritis, proton pump as target autoantigen of Th1-type cytotoxic T cells in, 120:377
Autoimmune hepatitis (AIH)
autoantibodies in, 120:1502–srr
cholestatic disease and, 120:1502–srr
clinical presentation of, 120:1502–srr
definition of, 120:1502–srr
diagnostic criteria for, 120:1502–srr
differential diagnosis of, 120:1502–srr
genetic heterogeneity of, 120:1502–srr
histology of, 120:1502–srr
immunoserological heterogeneity of, 120:1502–srr
liver transplantation for, 120:1502–srr
natural history of, 120:1502–srr
prognosis for, 120:1502 -srr
treatment of, 120:1502–srr
Autoimmune injury, hepatic, mechanisms of, 120:1485–srr
Azathioprine (AZA)
for autoimmune hepatitis, 120:1502–srr
for inflammatory bowel disease, 120:622
and 6-mercaptopurine, for refractory microscopic colitis, 120:1483–cr
AZT. *See* Zidovudine

Backwash ileitis, and colorectal carcinoma risk, in ulcerative colitis, 120:783–tmig, 120:841
Bacteria, and colitis in Tgε26 mice, 120:900
Bacterial overgrowth, in patients with gallstones, 120:1310–c
Bacterial translocation, in cirrhosis, prokinetics and, 120:314–ss
Bariatric surgery, for obesity, 120:669
Barrett's esophagus
cancer risk with, 120:1617, 120:1630
dysplasia in, evaluation of, fluorescence, reflectance, and light-scattering spectroscopy for, 120:1607, 120:1864–e
high-grade dysplasia in
long-term nonsurgical management of, 120:1617, 120:1864–e
and risk of carcinoma, 120:1630, 120:1864–e
photodynamic therapy for, persistent genetic abnormalities after, 120:1064–c, 120:1065–c
photodynamic therapy in, 120:785–gn
Bax gene, and butyric acid-induced apoptosis in colon cancer cells, 120:71
Behavior therapy, for obesity, 120:669
Behçet's disease, gastrointestinal, antitumor necrosis factor monoclonal antibody therapy for, 120:995–cr
Benzodiazepine receptor, peripheral type, and apoptosis induction in hepatic stellate cells, 120:1212, 120:1285–e
Bile acid
composition, sterol 12α-hydroxylase expression and (rat), 120:1801
jejunal absorption of, neurotensin and (rat), 120:151
metabolism, manipulation of, by activation of deorphanized nuclear receptors, 120:1054–ss
synthesis of
feedback regulation of, 120:1557–ss
nuclear receptors and, 120:1557–ss
Biliopancreatic diversion, for obesity, 120:669
BIM26226, and gastrointestinal motility, 120:331–tmig, 120:361
Blacks, colorectal cancer screening in, cost-effectiveness of, 120:848, 120:1043–e
Bleeding, with angiodysplasias of gastrointestinal tract, abnormal von Willebrand factor in, 120:346
Brain, cortical and subcortical regions in, activation of, by gastric distention, 120:369
Budd-Chiari syndrome
G20210A prothrombin gene mutation and, 120:1059–c
survival with, factors affecting, 120:578–ss
Budesonide, in autoimmune hepatitis, 120:1502–srr
Butyrate
cell differentiation and apoptosis induced by, resistance to, during spontaneous Caco-2 cell differentiation, 120:889
and 5-fluorouracil, antitumor synergy of, in human colorectal cancer xenografts, 120:874

Caffeine plus ephedrine, for obesity, 120:669
Calcitonin gene-related peptide (CGRP), and adaptive cytoprotection in gastric mucosa, 120:134
Calcium, influx, and mechanical tone in colon from dystrophic *(mdx)* mice, 120:1430
Calcium channels, L-type, in inflamed circular smooth muscle cells of colon (dog), 120:331–tmig, 120:480
Calcium-sensing receptor, in human antral gastrin cells, mechanism of action of, 120:1128, 120:1279–e
Camostat mesilate, in prevention of hepatic fibrosis (rat), 120:1784
Cancer
anal. *See* Anal canal, cancer of
celiac disease and, 120:636, 120:1526–aga
colon. *See* Colorectal cancer
esophageal. *See* Esophageal carcinoma
gastric. *See* Gastric cancer
lung. *See* Lung cancer
pancreatic. *See* Pancreatic cancer
rectal. *See* Colorectal cancer
targeted chemotherapy for, LST-2 and, 120:1689
Carbon monoxide, from heme catabolism protects against hepatobiliary dysfunction (rat), 120:1227, 120:1288–e
Carcinogenesis
in Caco-2 cells, PKC-δ and, 120:1700, 120:1868–e
hepatic, pathways of, genetic alterations and, 120:1763
Case Reports
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report, 120:995
Development of interstitial cells of Cajal in a full-term infant without an enteric nervous system, 120:561
Diffuse esophageal leiomyomatosis with perirectal involvement mimicking Hirschsprung disease, 120:216

Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the *c-kit* gene, 120:210
Human papillomavirus type 16-associated primary squamous cell carcinoma of the rectum, 120:988
Ischemic colitis during treatment with alosetron, 120:557
A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer, 120:1271
Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy, 120:984
Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine, 120:1483

CD34, in human biliary epithelial progenitor cells, 120:534

CDP571, for active Crohn's disease, 120:1317–tmig, 120:1330

Celiac disease
AGA medical position statement on, 120:1522–aga
AGA technical review on, 120:1526–aga
associated diseases, 120:636, 120:1526–aga
and autoimmune disease, 120:636
clinical features of, 120:636, 120:1526–aga
complications of, 120:1526–aga
definition of, 120:1526–aga
diagnosis of, 120:636, 120:1526–aga
epidemiology of, 120:636, 120:1526–aga
as food allergy, 120:1026–aga
genetics of, 120:1526–aga
historical perspective on, 120:1526–aga
and malignancy, 120:636, 120:1526–aga
pathogenesis of, 120:1526–aga
pathology of, 120:1526–aga
refractory, 120:636
screening for, 120:636
limitations of anti-guinea pig liver transglutaminase IgA in, 120:586–c
treatment of, 120:636, 120:1526–aga
types of, 120:1526–aga

Cell cycle, and intestinal cell differentiation, 120:423

Chemoattractants, epithelial
characterization of, 120:60, 120:291–e
interferon-inducible, production of, 120:49, 120:291–e

Chemokines, in regulation of lymphocyte homing to intestinal mucosa, 120:49, 120:60, 120:291–e

Chemotherapy
nausea and vomiting caused by, 120:263–aga
targeted, in gastrointestinal cancer, LST-2 and, 120:1689

Child-Turcotte-Pugh classification, of candidates for liver transplantation, 120:749

Chloride channels, epithelial cAMP-dependent, sucrase-isomaltase as, 120:117, 120:299–e

Chloride secretion, in intestinal epithelial T84 cells, potentiation of, by oxidants, 120:2–tmig, 120:89

Cholangiocarcinoma, *Helicobacter* sp. in liver and, 120:323–c

Cholangiocytes, oxidative DNA damage in, 120:190

Cholelithiasis, cholesterol
colonic deoxycholic acid formation in, 120:1310–c
MDR3 gene defect in, 120:1459, 120:1549–e

Cholestasis. *See also* Progressive familial intrahepatic cholestasis type 3
pathogenesis of, 119:321–c

Cholesterol
absorption of, pancreatic phospholipase A_2 and (mouse), 120:1193
metabolism of
ATP-binding cassette transporter A1 (ABCA1) and, 120:1203
manipulation of, by activation of deorphanized nuclear receptors, 120:1054–ss

Cholesterol gallstones
formation of
chromosomal organization of candidate genes involved in (mouse), 120:221–srr
colonic deoxycholic acid formation in, 120:1310–c
MDR3 gene defect and, 120:1459, 120:1549–e

Chromoendoscopy, 120:749

Cirrhosis
bacterial translocation in, prokinetics and, 120:314–ss
complications of, current management of, 120:726
health-related quality of life in, 120:170, 120:305–e

Cisapride, and bacterial translocation in cirrhosis, 120:314–ss

c-Jun N-terminal kinase (JNK), and butyric acid-induced apoptosis in colon cancer cells, 120:71

***c-kit* gene**
germline mutation of, and familial gastrointestinal stromal tumor with hyperpigmentation, 120:210–cr
in human biliary epithelial progenitor cells, 120:534

Claudins, expression and subcellular localization of, in gastrointestinal tract, heterogeneity in (rat), 120:411

Clevudine, therapy with, for hepatitis B, 120:1828–srr

Colitis
chronic Crohn's, screening and surveillance colonoscopy in, 120:783–tmig, 120:820
dextran sodium sulfate-induced, recovery from, in transgenic mice overexpressing growth hormone, 120:925
experimental, differential role of selectins in, 120:1072–tmig, 120:1162
microscopic, treatment with azathioprine and 6-mercaptopurine, 120:1483–cr
normal luminal bacteria and, in Tgϵ26 mice, 120:900

Colon
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
distal, findings in, and risk of proximal neoplasms, 120:1049–ss
inflamed, L-type calcium channels in (dog), 120:331–tmig, 120:480
muscle in, tachykinin receptor NK_1 on, immunohistochemical demonstration of (guinea pig), 120:1140
peristalsis in, tachykinin-dependent and -independent components of (guinea pig), 120:938
proximal, from dystrophic (*mdx*) mice, mechanical tone of, calcium influx and, 120:1430
in vivo absorption of medium-chain fatty acids *versus* short-chain fatty acids (rat), 120:1152

Colon cancer. *See* Colorectal cancer

Colonic crypts, Na^+-dependent fluid absorption in (rat), 120:144

Colonic transit, and deoxycholic acid metabolism in cholesterol cholelithiasis, 120:1310–c

Colonoscopy
in Crohn's disease, 120:783–tmig, 120:820
virtual, as screening tool, 120:1073–gn

Colorectal cancer. *See also* Hereditary nonpolyposis colorectal cancer (HNPCC)
antitumor synergy of 5-fluorouracil and 3*n*-butyrate in, 120:874

Caco-2 cells
differentiation of, phosphatidylinositol 3-kinase and, 120:1317–tmig, 120:1381, 120:1543–e
partial reversion of malignant phenotype in, PKC-δ and, 120:1700, 120:1868–e
resistance to butyrate-induced cell differentiation and apoptosis, 120:889
chemotherapy for, microsatellite instability as prognostic indicator in, 120:1309–c
circulating tumor cells in peripheral blood of patients with, prognostic significance of, 120:1071–tmig, 120:1084
growth of, COX-2 and HER-2/*neu* inhibitors and, 120:1713, 120:1872–e
individuals at risk for, identification of, 120:1317–tmig, 120:1356
inflammatory bowel disease and, 120:783–tmig, 120:820, 120:841, 120:1317–tmig, 120:1356
pathogenesis of, colonic luminal contents and, 120:332–tmig, 120:401
prevention of, advances in (future directions for), 120:3–gn
risk of, with *APC* I1307K mutation in Ashkenazi Jews, 120:331–tmig, 120:392
screening for, 120:333–gn
in chronic Crohn's colitis, 120:783–tmig, 120:820
colonoscopy in, 120:1049–ss, 120:1051–ss
distal colonic findings in, and risk of proximal neoplasms, 120:1049–ss
racial/ethnic patterns of disease and, 120:848, 120:1043–e
virtual colonoscopy in, 120:1073–gn
surveillance colonoscopy for, in chronic Crohn's colitis, 120:783–tmig, 120:820
in ulcerative colitis patients
backwash ileitis and, 120:783–tmig, 120:841
p53 gene and, 120:1877–ss
Combivir. *See* ZDV-3TC
Comment From the Editors
Editorial transition, 120:1577
Entangled in a Web(site)?, 120:1321
GERD remains an intriguing enigma, 120:787
Postapproval drug surveillance and the first principle of medicine, 120:5
Pump up the volume: a sound policy?, 120:1075
Remembering John Walsh: One of the prophets of GI, 120:335
Complement
activation of, induced by *Helicobacter pylori*, 120:1108
C5, inhibition of, effect on local and remote organ injury after intestinal ischemia-reperfusion (rat), 120:126
resistance to, by protectin-bound *Helicobacter pylori*, 120:332–tmig, 120:470
Computed tomography (CT), of pancreas, in diagnosis of pancreatitis, 120:682
Constipation
functional, prucalopride for, 120:331–tmig, 120:354
historical perspective on, 120:317–pmr
Correspondence
Abnormal hepatic sinusoidal bile acid transport: new insights into the pathogenesis of cholestasis?, 120:321
API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of *H. pylori* eradication treatment in low-grade gastric MALT lymphoma, 120:1884
Differential HFE allele expression in hemochromatosis heterozygotes, 120:1308
G20210A prothrombin gene mutation and other thrombophilic polymorphisms in patients with portal or hepatic venous thrombosis, 120:1059
Helicobacter pylori infection and gastric cancer, 120:324
Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma, 120:323
Heparin therapy for ulcerative colitis, 120:1307
Hepatitis B infection in heart transplant recipients, 120:1311
Hepatitis B virus genotypes and hepatocellular carcinoma in Japan, 120:1564
Identification of motilin-related peptide, 120:588
Increased levels of factor VIII:C as a possible risk factor for portal, splenic, and mesenteric vein thrombosis, 120:1563
Intestinal motility and bacterial overgrowth in patients with gallstones, 120:1310
Intractable insomnia after cessation of treatment with thalidomide, 120:1567
Laparoscopic appendectomy in patients with refractory ulcerative colitis, 120:1562
Limitations of anti-guinea pig liver transglutaminase IgA in screening of celiac disease, 120:586
Mesalamine maintenance therapy for Crohn's disease, 120:585
Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy, 120:1309
Motilin-related peptide and ghrelin: lessons from molecular techniques, peptide chemistry, and receptor biology, 120:587
Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis, 120:1061
Optimal cases and sites to search for primary microbial agents in Crohn's disease, 120:1066
Organic anion-transporting polypeptides: expression cloning and functional tests, 120:1887
Organization of intestinal pacemakers, 120:319
Pathogenesis of diclofenac enteropathy, 120:1885
Photodynamic therapy and genetic abnormalities, 120:1065
Significance of genetic abnormalities after photodynamic therapy, 120:1064
Somatic mutation of the β_2-microglobulin gene associates with unfavorable prognosis in gastrointestinal cancer of the microsatellite mutator phenotype, 120:1565
SPINK1 mutations in chronic pancreatitis, 120:1060
Successful orthotopic liver transplantation, 120:1561
Variability of serologic testing for *H. pylori* using U.S. and Peruvian antigens, 120:325
When can unfractionated heparin really be useful in the treatment of ulcerative colitis?, 120:1306
Why the mesenteric margin?, 120:1885
Couric, Katie, and CRC screening, 120:333–gn
Cow's milk allergy
disorders associated with, 120:1026–aga
gastroesophageal reflux disease associated with, in infants, 120:1026–aga

Coxib, therapy with, during NSAID use, 120:594
Crixivan. *See* Indinavir
Crohn's disease (CD)
ASCA (anti-*Saccharomyces cerevisiae* antibody) assays in, comparative study of, 120:827
course of, smoking cessation and, 120:1071–tmig, 120:1093
maintenance of remission in, methotrexate for, 120:1553–ss
mesalamine maintenance therapy for, 120:585–c
patient education about, 120:317–pmr
perianal fistulae in, initial medical management for, cost-utility of, 120:1640
primary microbial agents in, optimal cases and sites to search for, 120:1066–c
screening and surveillance colonoscopy in, 120:783–tmig, 120:820
treatment of, 120:317–pmr
anti-TNF antibody for, ANCA pattern and LTA haplotype and, 120:1347
engineered human antibody to TNF (CDP571) for, 120:1317–tmig, 120:1330
novel therapies for, 120:308–ss
subcutaneous antisense ICAM-1 for, absence of efficacy of, 120:1317–tmig, 120:1339
Cryptosporidiosis, in HIV-infected (AIDS) patient, HAART-related resolution of, 120:984–cr
Cryptosporidium parvum
enterocyte resistance against, IFN-γ–mediated, 120:99
and NF-κB activation in biliary epithelia, and prevention of epithelial cell apoptosis, 120:1774
Cyclooxygenase (COX), COX-2
and colorectal carcinoma growth, 120:1713, 120:1872–e
and gastroprotective prostaglandins, 120:784–tmig, 120:867
inhibitor, therapy with, during NSAID use, 120:594
and persistent postinfective enteric muscle dysfunction (mouse), 120:1713
TNF-α-induced expression of, in colonic epithelial cells, phosphatidylinositol 3-kinase and, 120:1117
transcription in human colon carcinoma cells, colonic luminal contents and, 120:332–tmig, 120:401
Cyclophosphamide, for autoimmune hepatitis, 120:1502–srr
Cyclosporine
for autoimmune hepatitis, 120:1502–srr
as single therapy for acute ulcerative colitis, 120:1317–tmig, 120:1323, 120:1541–e
Cystic fibrosis transmembrane conductance regulator, mutations, and chronic pancreatitis, 120:682
Cytochrome P-450
CYP8b1, and regulation of bile acid pool composition (rat), 120:1801
CYP4502E1, ethanol-induced, and retinoic acid metabolism (rat), 120:179
Cytokines, therapy with, for hepatitis B, 120:1828–srr

ddC. *See* Zalcitabine
ddI. *See* Didanosine
Delavirdine, GI toxicity and GI-associated drug interactions of, 120:607
Dendritic cells, impaired allostimulatory function of, in chronic hepatitis C, 120:512
Deoxycholic acid, colonic formation of, and cholesterol cholelithiasis, 120:1310–c
Dermatitis herpetiformis, 120:1526–aga
Developmental biology, of gastrointestinal tract, 120:1883–pmr
Diabetic gastropathy, sildenafil therapy in animal models of, 120:576–ss
Diarrhea, acute, in children, management of, 120:783–tmig, 120:799
Diclofenac, enteropathy induced by, pathogenesis of, 119:1885–c
Didanosine, GI toxicity and GI-associated drug interactions of, 120:607
Diet therapy, for obesity, 120:669
Disaccharides, and IL-8 and IL-1β secretion by intestinal epithelial cells, 120:449
Divalent metal transporter 1
expression of, in iron deficiency and iron overload, 120:1317–tmig, 120:1412
intestinal iron uptake determined by, in HFE-deficient mice with hemochromatosis, 120:1420
DNA (deoxyribonucleic acid)
base excision repair, nitric oxide-mediated inhibition of, 120:190
oxidative damage, in cholangiocytes, 120:190
Drug development, postapproval surveillance in, and interests of patients, 120:5–ce
d4T. *See* Stavudine
Duodenal switch, for obesity, 120:669
Dyspepsia, management of, 120:1298–ss

Economics
of colorectal cancer screening, racial/ethnic patterns of disease and, in U.S., 120:848, 120:1043–e
of HCFA policy, effects on gastroenterologists and Medicare patients, 120:3–gn
of initial medical management for Crohn's disease perianal fistulae, 120:1640
of managing GI risk in patients taking NSAIDs, 120:594
of research funding initiative in Germany, 120:334–gn
Editorials
Apoptosis–programmed cell death and its relevance to gastrointestinal epithelium: survival signal from the matrix, 120:294
Carbon monoxide and sepsis: is a toxic gas good for your liver?, 120:1288
Chemokines regulate lymphocyte homing to the intestinal mucosa, 120:291
Chronic liver disease and health-related quality of life, 120:305
Colorectal cancer: not an equal opportunity cancer, 120:1043
Disputing dysplasia, 120:1864
Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology, 120:1872
Gastric cardia cancer and dietary fiber, 120:568
GLP-2 as therapy for the short-bowel syndrome, 120:1041
How can mathematics help us understand HCV?, 120:1546
Human papillomavirus infection: an emerging problem in anal and other squamous cell cancers, 120:1046
Identification of a new chloride channel: a sweet story?, 120:299
Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue, 120:1281
Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone?, 120:1541
Irritable bowel syndrome in childhood, 120:287

Is EXO1 a colon cancer predisposition gene?, 120:1860
Liver fibrosis and Na^+/H^+ exchange, 120:572
MDR3 mutations: a glimpse into Pandora's box and the future of canalicular pathophysiology, 120:1549
Octreotide and its effects on portal circulation, 120:303
Progress in understanding acalculous gallbladder disease, 120:570
Protein kinase C isozymes in colon carcinogenesis: guilt by omission, 120:1868
Sugar pills for pancreatic cancer: the benefits of becoming (insulin) sensitive, 120:1291
Transepithelial signaling: making sense of stomach contents, 120:1279
The up-and-down of hepatic stellate cells in tissue injury: apoptosis restores cellular homeostasis, 120:1285
Will impedance testing rewrite the book on GERD?, 120:1862
The Yin and Yang of intestinal differentiation: key roles for lipid signaling, 120:1543

Efavirenz, GI toxicity and GI-associated drug interactions of, 120:607

Emtricitabine, therapy with, for hepatitis B, 120:1828–srr

Endoscopic diagnostics, 120:763, 120:1304–pmr

Endoscopic retrograde cholangiopancreatography (ERCP), pancreatitis induced by, protection against, by IL-10, 120:332–tmig, 120:498

Endoscopic retrograde pancreatography (ERP), in diagnosis of pancreatitis, 120:682

Endoscopic ultrasound, in diagnosis of pancreatitis, 120:682

Endoscopy
in follow-up of high-grade dysplasia in Barrett's esophagus, 120:1617
gastrointestinal, 120:1304–pmr

Enteral nutrition, for alcoholic hepatitis, 120:1053–ss

Enteric nervous system, and development of interstitial cells of Cajal, in human small intestine, 120:561–cr

Enterocolitis syndrome, dietary (food) protein–induced, 120:1026–aga

Enterocytes, high-affinity basolateral glycine uptake in, GLYT1 and, 120:439

Enteropathy
diclofenac, pathogenesis of, 119:1885–c
dietary (food) protein–induced, 120:1026–aga

Enzyme, functioning as ion channel, 120:117, 120:299–e

Eosinophilic esophagitis, and GER, in adults and children, 120:1026–aga

Eosinophilic gastroenteritis, 120:1026–aga

Epidermal growth factor (EGF) receptor
blockade
and colorectal carcinoma growth, 120:1713, 120:1872–e
therapeutic applications of, 120:1713, 120:1872–e
and stress-induced expression of EGF-like growth factors in gastric epithelial cells (rat), 120:108

Epilepsy, abdominal, 120:263–aga

Epithelium
apoptosis in, signal transduction during, 120:79, 120:294–e
biliary
Cryptosporidium parvum and NF-κB activation in, and prevention of epithelial cell apoptosis, 120:1774
progenitor cells of, 120:534
cell biology in, keratin 19 promoter in, 120:1728
colonic
absorption of medium-chain fatty acids (rat), 120:1152
resistance to butyrate-induced cell differentiation and apoptosis, 120:889
TNF-α-induced COX-2 expression in, phosphatidylinositol 3-kinase and, 120:1117
follicle-associated, lymphocyte-dependent development of, in Peyer's patches (mouse), 120:1173
gastric, stress-induced expression of EGF-like growth factors, EGFR-mediated (rat), 120:108
intestinal
cell differentiation in, cell cycle and, 120:423
chloride secretion in, potentiation of, by oxidants, 120:2–tmig, 120:89
dysfunction, caused by inhibition of Na^+, K^+-ATPase by interferon γ, 120:1393
hPepT1 expression in, in inflammatory bowel disease, 120:1657
IL-8 and IL-1β secretion by, disaccharides and, 120:449
lymphocyte chemoattractants produced by
characterization of, 120:60, 120:291–e
production of, 120:49, 120:291–e
tachykinin receptor NK_1 on, immunohistochemical demonstration of (guinea pig), 120:1140

Epivir. *See* Lamivudine

ErbB receptor, HER-2/*neu*, and colorectal carcinoma growth, 120:1721, 120:1872–e

Esophageal carcinoma
photodynamic therapy for, 120:785–gn
risk of, high-grade dysplasia in Barrett's esophagus and, 120:1617, 120:1630

Esophageal manometry, for diagnosis of achalasia, 120:783–tmig, 120:789

Esophagus. *See also* Barrett's esophagus
diffuse leiomyomatosis of, 120:216–cr
high-grade dysplasia in, photodynamic therapy for, 120:785–gn
nerve-mediated contractions in, tachykinins and, 120:1–tmig, 120:39

Ethanol
and chronic pancreatitis, 120:682
induction of CYP4502E1, and retinoic acid metabolism (rat), 120:179
liver disease caused by, risk of, homozygosity for alanine in mitochondrial targeting sequence of SOD and, 120:1318–tmig, 120:1468
liver injury caused by, reduction of, by superoxide dismutase (rat), 120:1241

Etodolac, gastrointestinal events related to, risk of, 120:594

Exercise therapy, for obesity, 120:669

***EXO1* gene,** germline variants of, in hereditary nonpolyposis colorectal cancer, 120:1580–rc, 120:1860–e

Farnesoid X receptor, and cholesterol and bile acid metabolism, 120:1054–ss

Fas protein, apoptosis mediated by, inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810

Fat digestion, and modulation of gastrointestinal sensations in gastric distention, 120:1071–tmig, 120:1100

Fatty acids, medium-chain, colonic absorption of (rat), 120:1152

Fenfluramine plus phentermine, for obesity, 120:669

Ferroportin 1, expression of, in iron deficiency and iron overload, 120:1317–tmig, 120:1412

Fiber, dietary
intake of, and risk of gastric cardia cancer, 120:331–tmig, 120:387, 120:568–e
in treatment of irritable bowel syndrome, 120:652
***FIC1* gene,** mutation, in Amish kindred, 119:321–c
5-Fluorouracil, and 3*n*-butyrate, antitumor synergy of, in human colorectal cancer xenografts, 120:874
Focal adhesion kinase, cleavage of, during apoptosis, 120:79, 120:294–e
Food allergy
clinical manifestations of, 120:1026–aga
diagnostic criteria for, 120:1026–aga
epidemiology of, 120:1026–aga
evaluation of
AGA technical review on, 120:1026–aga
guidelines for, AGA medical position statement on, 120:1023–aga
pathophysiology of, 120:1026–aga
Food and Drug Administration (FDA), proposal to increase public access to information on xenotransplantation and gene therapy trials, 120:786–gn
Food protein, immediate (IgE-mediated) gastrointestinal reactions to, 120:1026–aga
Fortovase. *See* Saquinavir

GABA$_B$ receptors, and vagal motor control of lower esophageal sphincter, 120:1749
Gallbladder
chronic acalculous disease of, muscle dysfunction in, 120:506, 120:570–e
contraction of, GRP receptor blockade and, 120:331–tmig, 120:361
motility, and chronic acalculous disease, 120:506, 120:570–e
Gallstones, cholesterol, formation of, chromosomal organization of candidate genes involved in (mouse), 120:221–srr
Gastric acid, secretion, KCNQ1 in, 120:1363
Gastric banding, for obesity, 120:669
Gastric bypass, for obesity, 120:669
Gastric cancer
of cardia, cereal fiber intake and, 120:331–tmig, 120:387, 120:568–e
Helicobacter pylori and, 120:324–c
Gastric distention
cortical and subcortical regions activated by, 120:369
gastrointestinal sensations induced by, fat digestion and, 120:1071–tmig, 120:1100
Gastric emptying, GRP receptor blockade and, 120:331–tmig, 120:361
Gastrin-releasing peptide (GRP) receptors, in gastric emptying, gallbladder contraction, and small intestinal transit, 120:331–tmig, 120:361
Gastritis, autoimmune, proton pump as target autoantigen of Th1-type cytotoxic T cells in, 120:377
GASTROENTEROLOGY
editorial transition, 120:1577–ce
special issue on therapeutics and diagnostics, introduction to, 120:593
Gastroenterology, evidence-based, 120:1559–pmr
Gastroenterology News
Bill seeks to reform, educate on Medicare regulations, 120:1320
Biomedical research funding on the rise in Japan, 120:1074
Couric, Tartikoff to push CRC screening message in March, 120:333
FDA seeks to increase access to information on xenotransplantation, gene therapy trials, 120:786
The future of colon cancer prevention, 120:3
HCFA policy hurts gastroenterologists and Medicare patients, AGA charges, 120:3
Major funding initiative in Germany enhances research efforts, 120:334
New AGA president outlines goals, 120:786
New leadership in Washington: implications for gastroenterology, 120:333
Nutrition and obesity, xenotransplantation among topics to be covered at DDW 2001, 120:1073
Nutrition moves beyond weighty issues, 120:1319
Pegylated interferon for treatment of hepatitis C, 120:3
Photo finish for Barrett's esophagus, other digestive tract lesions?, 120:785
Radiologist sees a future for virtual colonoscopy as screening tool, 120:1073
Student loan burden may be eased, 120:1320
Gastroesophageal reflux disease (GERD), 120:583–pmr
acid, nonacid, and gas, during 24-hour pH-impedance recordings, 120:1588, 120:1862–e
acid and nonacid, simultaneous intraesophageal impedance and pH measurement of, effect of omeprazole, 120:1599, 120:1862–e
associated with cow's milk allergy, in infants, 120:1026–aga
diagnosis of, 120:787–ce
eosinophilic esophagitis and, in adults and children, 120:1026–aga
pathogenesis of, 120:787–ce
treatment of, 120:787–ce
Gastrointestinal motility, 120:1056–pmr
mechanisms for, 120:331–tmig, 120:361, 120:480
tachynergic and cholinergic transmission in, 120:938
Gastrointestinal stromal tumor, familial, with hyperpigmentation, c-*kit* gene mutation and, 120:210–cr
Gastrointestinal tract, claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
Gastrointestinal transit
GRP receptor blockade and, 120:331–tmig, 120:361
prucalopride and, in functional constipation, 120:331–tmig, 120:354
Gastroparesis
intractable nausea and vomiting with, 120:263–aga
therapy for, 120:576–ss
Gastroplasty, for obesity, 120:669
G cells, calcium-sensing receptor on, mechanism of action of, 120:1128, 120:1279–e
Gene therapy, trials of, information on, FDA seeks to increase access to, 120:786–gn
Genetic testing, for hereditary nonpolyposis colorectal cancer, microsatellite instability and, 120:1–tmig, 120:21
Ghrelin
and appetite regulation, 120:337–rc
and motilin-related peptide, 120:587–c, 120:588–c
structure of, 120:337–rc
Glisson, Francis, 120:1362
Glucagon-like peptide 2, in treatment of short-bowel syndrome, 120:783–tmig, 120:806, 120:1041–e
Gluten
in medications, 120:636
total avoidance of, in treatment of celiac disease, 120:636, 120:1526–aga
Glycine, high-affinity basolateral uptake of, in enterocytes, GLYT1 and, 120:439
Goblet cells, differentiation of, regulation by keratinocyte growth factor, 120:1372

Growth hormone (GH)
and recovery from dextran sodium sulfate-induced colitis (mouse), 120:925
therapy with, for Crohn's disease, 120:308–ss

Halsted, William Stewart, 120:386
Health Care Finance Administration, policy, effects on gastroenterologists and Medicare patients, 120:3–gn
Health care quality, volume/outcome relationship in, 120:1075–ce
Health-related quality of life, in chronic liver disease, 120:170, 120:305–e
Heart transplantation, recipients
hepatitis B in, 120:1311–c
viral hepatitis in, 120:1561–c
Heidenhain, Rudolf, 120:1083
***Helicobacter* sp.,** in liver from patients with cholangiocarcinoma and hepatocellular carcinoma, 120:323–c
Helicobacter pylori
complement activation induced by, 120:1108
eradication
in gastric MALT lymphoma, API2-MALT1 chimeric transcript as predictive marker for responsiveness to, 120:1884–c
versus prompt endoscopy, for dyspepsia, 120:1298–ss
and gastric cancer, 120:324–c
and NSAID use, 120:594
protectin-bound
complement-induced lysis prevented by, 120:332–tmig, 120:470
prevention of complement-induced lysis, 120:332–tmig
serologic testing for, using U.S. and Peruvian antigens, 120:325–c
Heme catabolism, carbon monoxide from, and protection against hepatobiliary dysfunction (rat), 120:1227, 120:1288–e
Hemochromatosis
clinical features of, 120:718
diagnosis of, 120:718
differential HFE allele expression in, 120:1308–c
duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404
genetics of, 120:718
in HFE-deficient mice, and intestinal iron uptake determined by divalent metal transporter 1, 120:1420
management of, 120:718
pathophysiology of, 120:718
screening for
family, 120:718
population, 120:718
Heparan sulfate, disaccharides derived from, and IL-8 and IL-1β secretion by intestinal epithelial cells, 120:449
Heparin
disaccharides derived from, and IL-8 and IL-1β secretion by intestinal epithelial cells, 120:449
unfractionated, for ulcerative colitis, comparison with methylprednisolone, 120:1306–c, 120:1307–c
Hepatic vein, thrombosis, G20210A prothrombin gene mutation and, 120:1059–c
Hepatitis
alcoholic, nutritional therapy for, 120:1053–ss
autoimmune. *See* Autoimmune hepatitis (AIH)
viral, in heart transplant recipients, 120:1311–c, 120:1561–c
Hepatitis B/Hepatitis B virus (HBV)
advanced, antiviral therapy for, 120:1828–srr
animal models of, 120:1828–srr
chronic
acute flares of, 120:1009–srr
in children, 120:1828–srr
gene expression in, cDNA microarray analysis of, 120:955
HBeAg-negative
interferon α therapy in, 120:1828–srr
lamivudine therapy for, 120:1828–srr
HBeAg-positive
interferon α therapy in, 120:1828–srr
lamivudine therapy for, 120:1828–srr
liver histology in, 120:1828–srr
DNA, tests for, 120:1828–srr
drug resistance in, molecular anatomy and pathophysiologic implications of, 120:1000–srr
epidemiology of, 120:1828–srr
flares of
antiviral therapy-induced, 120:1009–srr
HBV genotypic variation and, 120:1009–srr
lamivudine therapy and, 120:1000–srr
other viral infection and, 120:1009–srr
genotypes, and hepatocellular carcinoma, in Japan, 120:1564–c
in heart transplant recipients, 120:1311–c, 120:1561–c
and hepatocellular carcinoma, surveillance for, 120:1828–srr
immunopathogenesis of, 120:1828–srr
lamivudine resistance in, 120:1828–srr
natural history of, 120:1828–srr
polymerase, 120:1000–srr
recurrence after liver transplantation
prevention of
combination therapy for, 120:1828–srr
HBIg for, 120:1828–srr
treatment of, 120:1828–srr
treatment of
in HIV-infected (AIDS) patients, 120:1828–srr
molecular approaches to, 120:1828–srr
nucleoside analogs for, 120:1828–srr
recommendations for, 120:1828–srr
vaccine against, 120:1828–srr
and multiple sclerosis, 120:1880–ss
variants and mutants of, 120:1828–srr
virology of, 120:1828–srr
Hepatitis C/Hepatitis C virus (HCV)
chronic
allostimulatory defect of dendritic cells in, 120:512
gene expression in, cDNA microarray analysis of, 120:955
in heart transplant recipients, 120:1561–c
hepatic fibrosis in, response to interferon therapy, 120:579–ss
in HIV-infected (AIDS) patients, management of, 120:607
information on, for children, 120:1056–pmr
management of, 120:1878–ss
mother-to-child transmission of, prevention of, 120:1555–ss
outcome of, prediction of, 120:312–ss
prognosis for, 120:1878–ss
quasispecies of, prognostic significance of, 120:312–ss
recurrence of, after liver transplantation, 120:749
treatment of, pegylated interferon for, 120:3–gn
viral kinetics with, 120:1318–tmig, 120:1438, 120:1546–e
Hepatocellular carcinoma (HCC)
genetic alterations in, 120:1763
HBV genotypes and, in Japan, 120:1564–c
Helicobacter sp. in liver and, 120:323–c
prevention of, by interferon, 120:1301–ss

surveillance for, in hepatitis B, 120:1828–srr
Hepatocytes
Fas-mediated apoptosis in, inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810
TNF-α and Fas-mediated apoptosis in, NF-κB activation and iNOS in (mouse), 120:1251
transplantation of, 120:749
Hepatology, evidence-based, 120:1559–pmr
Hepatorenal syndrome, treatment of, 120:726
Hereditary hemochromatosis. *See* Hemochromatosis
Hereditary nonpolyposis colorectal cancer (HNPCC)
atypical, germline variants of *EX01* gene in, 120:1580–rc, 120:1860–e
detection of, by screening for tumor microsatellite instability before germline genetic testing, 120:1–tmig, 120:21
HER-2/*neu*, and colorectal carcinoma growth, 120:1713, 120:1872–e
***HFE* gene**
differential allelic expression of, in hemochromatosis, 120:1308–c
knockout models of, 120:718
mutations, analysis of, in liver disease, 120:718
Highly active antiretroviral therapy (HAART)
GI-associated drug interactions of, 120:607
for HIV-1 infection
adverse effects and side effects of, 120:607
efficacy of, 120:607
and mucosal immunity, 120:984–cr
Hirschsprung's disease
differential diagnosis of, 120:216–cr
single-stage operations for, 120:1299–ss
Histoacryl, in management of gastric varices, 120:1875–ss
HIVID. *See* Zalcitabine
HIV-infected (AIDS) patients. *See also* Human immunodeficiency virus (HIV-1)
hepatitis B in, treatment of, 120:1828–srr
hepatitis C in, management of, 120:607
H^+,K^+-ATPase. *See* Proton pump
hPepT1, colonic epithelial expression of, in inflammatory bowel disease, 120:1657
Human immunodeficiency virus (HIV-1). *See also* HIV-infected (AIDS) patients
infection
management of, gastrointestinal aspects of, 120:607
pathogenesis of, gastrointestinal aspects of, 120:607
transmission of, gastrointestinal mucosa and, 120:607
Human papilloma virus (HPV)
and high-grade dysplasia in anal canal, 120:784–tmig, 120:857, 120:1046–e
and risk of anal canal cancer, 120:784–tmig, 120:857, 120:1046–e
type 16, and primary squamous cell carcinoma of rectum, 120:988–cr, 120:1046–e
Hydroxyurea, therapy with, GI toxicity and GI-associated drug interactions of, 120:607
Hypercalcemia, and chronic pancreatitis, 120:682
Hyperlipidemia, and chronic pancreatitis, 120:682
Hyperpigmentation, familial gastrointestinal stromal tumor with, 120:210–cr
Hypnotherapy, in treatment of irritable bowel syndrome, 120:652

Ibuprofen, gastrointestinal events related to, risk of, 120:594
Ileitis, after intracellular parasite infection, regulation by TGF-β-producing intraepithelial lymphocytes (mouse), 120:914
Image of the Month
complications of endoscopic variceal sclerotherapy, 120:336
hepatic arteriovenous malformations, 120:1579
ileocecal tuberculosis, 120:1076
pheochromocytoma, 120:6
Salmonella aortitis, 120:1322
von Hippel-Lindau (VHL) disease, 120:788
Immune cells, hepatic, 120:250–srr
Immunodiagnostics, in inflammatory bowel disease, 120:622
Immunoglobulin A, anti-guinea pig liver transglutaminase, in screening for celiac disease, limitations of, 120:586–c
Immunomodulation, for inflammatory bowel disease, 120:622
Immunosuppression
for autoimmune hepatitis, 120:1502–srr
evolving strategies for, 120:749
historical perspective on, 120:749
for inflammatory bowel disease, 120:622
Impedance testing, in gastroesophageal reflux disease, 120:1588, 120:1599, 120:1862–e
Indinavir, GI toxicity and GI-associated drug interactions of, 120:607
Indomethacin
gastrointestinal events related to, risk of, 120:594
inflammation induced by, vascular anatomy in, 120:1885–c
Inflammation
colonic, down-regulation of L-type calcium channels in (dog), 120:331–tmig, 120:480
in ischemia-reperfusion injury, PPARγ and (mouse), 120:332–tmig, 120:460
mucosal, normal luminal bacteria and, in Tgε26 mice, 120:900
Inflammatory bowel disease (IBD). *See also* Crohn's disease (CD); Ulcerative colitis (UC)
ASCA (anti-*Saccharomyces cerevisiae* antibody) assays in, 120:827
colonic epithelial hPepT1 expression in, 120:1657
and colorectal cancer risk, 120:783–tmig, 120:816, 120:820, 120:841
family history and, 120:816, 120:1317–tmig, 120:1356
diagnosis of, 120:622, 120:1057–pmr
ecotherapeutics for, 120:622
immunodiagnostics of, 120:622
immunotherapeutics for, 120:622
management of, 120:622, 120:1057–pmr
new modalities for, 120:1317–tmig, 120:1323, 120:1330, 120:1339
probiotic therapy in, 120:622, 120:1297–ss
in spouses and their offspring, 120:816
susceptibility locus for, on X chromosome, evidence for, 120:834
treatment of, growth hormone as potential agent in, 120:925
Infliximab
for Crohn's disease, clinical responses to, effect of ANCA pattern and LTA haplotype on, 120:1347
for gastrointestinal Behçet's disease, 120:995–cr
for initial medical management of Crohn's perianal fistulae, cost-utility of, 120:1640
Infrared imaging, 120:749
Insomnia, intractable, after cessation of thalidomide therapy, 120:1567–c
Insulin resistance
and obesity, in pancreatic carcinogenesis, 120:1072–tmig, 120:1263, 120:1291–e
and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281–e

Interferon
effect on hepatic fibrosis in chronic hepatitis C, 120:579–ss
IFN-α
for children with chronic hepatitis B, 120:1828–srr
effect on natural history of chronic hepatitis B, 120:1828–srr
for HBeAg-negative chronic hepatitis B, 120:1828–srr
for HBeAg-positive chronic hepatitis B, 120:1828–srr
plus lamivudine, therapy with, in chronic hepatitis B, 120:1828–srr
IFN-β, and prevention of hepatocellular carcinoma in hepatitis C, 120:1301–ss
IFN-γ
effects on intestinal epithelial transport and barrier function, 120:1393
and enterocyte resistance against *Cryptosporidium parvum*, 120:99
pegylated, for hepatitis C, 120:3–gn
viral kinetics with, 120:1318–tmig, 120:1438, 120:1546–e
Interleukin(s)
IL-2, therapy with, GI toxicity and GI-associated drug interactions of, 120:607
IL-8 and IL-1β, secretion by intestinal epithelial cells, disaccharides and, 120:449
IL-10
protection against ERCP-induced pancreatitis, 120:332–tmig, 120:498
therapy with, in inflammatory bowel disease, 120:1297–ss
Internet, medical information on, 120:1321–ce
Interstitial cells of Cajal, development of, enteric nervous system and, in human small intestine, 120:561–cr
Intestinal metaplasia, diagnosis of, Optical coherence tomography in, 120:1–tmig, 120:7
Invirase. *See* Saquinavir
Iron. *See also* Stimulator of Fe transport (SFT)
duodenal absorption of, effect on iron homeostasis, 120:1317–tmig, 120:1412
intestinal uptake of, by divalent metal transporter 1, in HFE-deficient mice with hemochromatosis, 120:1420
Iron deficiency
duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404
expression of divalent-metal transporter 1 and ferroportin 1 in, 120:1317–tmig, 120:1412
Iron overload syndromes. *See also* Hemochromatosis
classification of, 120:718
expression of divalent-metal transporter 1 and ferroportin 1 in, 120:1317–tmig, 120:1412
Irritable bowel syndrome (IBS), 120:1559–pmr
in children, 120:1–tmig, 120:31, 120:287–e
diagnostic criteria for, 120:652
epidemiology of, 120:652
management of, 120:652
novel and experimental therapies for, 120:652
natural history of, 120:652
pathophysiology of, 120:652
variants of, 120:652
Ischemia-reperfusion injury
anti-inflammatory activity in, PPARγ and (mouse), 120:332–tmig, 120:460
intestinal
complement C5 inhibition and (rat), 120:126
remote organ injury after, complement C5 inhibition and (rat), 120:126
Ischemic colitis, during alosetron therapy, 120:557–cr
Isenberg, Jon I., President of AGA, 120:1518–aga
goals of, 120:786–gn

Japan
biomedical research funding in, 120:1074–gn
HBV genotypes and hepatocellular carcinoma in, 120:1564–c
Jejunoileal bypass, for obesity, 120:669
Jejunum, bile acid absorption in, neurotensin and (rat), 120:151
Julius M. Friedenwald Medal, presentation to Don W. Powell, 120:1854–aga

Kaletra. *See* ABT 378
Keratinocyte growth factor, and goblet cell differentiation, 120:1372
Keratin 19 promoter, and cell-specific targeting of genes in transgenic mice, 120:1728
Ketorolac, gastrointestinal events related to, risk of, 120:594
Kupffer cell, in alcoholic steatosis (rat), 120:581–ss

Lamivudine
for chronic hepatitis B
and development of YMDD mutant virus, 120:1000–srr, 120:1561–c
in HBeAg-negative disease, 120:1828–srr
in HBeAg-positive disease, 120:1828–srr
GI toxicity and GI-associated drug interactions of, 120:607
plus IFN-α, therapy with, in chronic hepatitis B, 120:1828–srr
resistance, in hepatitis B, 120:1000–srr, 120:1828–srr
Leiomyomatosis, diffuse esophageal, 120:216–cr
Light-induced fluorescence spectroscopy, 120:749
Light-scattering spectroscopy, 120:749
Lipids, duodenal, gastrointestinal sensations induced by, fat digestion and, 120:1071–tmig, 120:1100
Liver
alcoholic disease of, risk of, homozygosity for alanine in mitochondrial targeting sequence of SOD and, 120:1318–tmig, 120:1468
alcoholic steatosis in, Kupffer cell and (rat), 120:581–ss
alcohol-induced injury of, reduction of, by superoxide dismutase (rat), 120:1241
anatomy of, 120:1304–pmr
arteriovenous malformations in, 120:1579–im
autoimmune injury of, mechanisms of, 120:1485–srr
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
diseases of
autoantibodies in, 120:239–srr
chronic, and health-related quality of life, 120:170, 120:305–e
diagnosis and management of, 120:584–pmr
HFE gene mutation analysis in, 120:718
fibrosis
in hepatitis C, response to interferon therapy, 120:579–ss
Na^+/H^+ exchanger and (rat), 120:545, 120:572–e
prevention of, by protease inhibitor (rat), 120:1784
healthy, immunology of, 120:250–srr
Helicobacter sp. in, 120:323–c
organic anion-transporting polypeptides (OATPs) of, functional comparison of, 120:525

retinoic acid metabolism, ethanol-induced CYP4502E1 and (rat), 120:179
sinusoidal bile acid uptake, impaired, in Amish kindred, 119:321–co
Liver/kidney microsome type 1, antibody to, in liver disease, 120:239–srr
Liver transplantation
for autoimmune hepatitis, 120:1502–srr
contraindications to, 120:749
current status of, 120:749
historical perspective on, 120:749
indications for, 120:749
listing criteria for, 120:749
living donor, 120:749
novel approaches to, 120:749
organ shortage and, 120:749
recurrent disease after, 120:749
selection criteria for, 120:749
split, 120:749
xenotransplantation for, 120:749
Liver X receptors, and cholesterol and bile acid metabolism, 120:1054–ss
Loperamide, in treatment of irritable bowel syndrome, 120:652
Lopinavir-ritonavir, therapy with, GI toxicity and GI-associated drug interactions of, 120:607
Lower esophageal sphincter (LES), vagal motor control of, site of action of GABAB receptor for, 120:1749
LST-2, and targeted chemotherapy for gastrointestinal cancer, 120:1689
Lung cancer, and Zollinger-Ellison syndrome, 120:1271–cr
Lung injury, after intestinal ischemia-reperfusion, anti-C5 therapy and (rat), 120:126
Lymphoma, MALT, gastric, 120:1884–c
Lymphotoxin
alpha (LTA), haplotype, and response to infliximab in Crohn's disease, 120:1347
and M cell development, in Peyer's patches (mouse), 120:1173

Magnetic resonance imaging (MRI), in diagnosis of pancreatitis, 120:682
Magnification endoscopy, 120:749
Major histocompatibility complex (MHC), class I molecules, expression of, intestinal epithelial transport of bacterial peptides and, 120:1657
Matrix metalloproteinase (MMP), in inflammatory bowel disease, 120:622
M cells, mature lymphocyte-independent development of, in Peyer's patches (mouse), 120:1173
Medicare
HCFA policy and, 120:3–gn
regulations, legislation aimed at reform of, and education on, 120:1320–gn
Meloxicam, gastrointestinal events related to, risk of, 120:594
6-Mercaptopurine (6-MP)
and azathioprine, for refractory microscopic colitis, 120:1483–cr
for inflammatory bowel disease, 120:622
Mesalamine, for Crohn's disease, as maintenance therapy, 120:585–c
Mesenteric vein, thrombosis
anticoagulant therapy for, 120:578–ss
increased levels of factor VIII:C as risk factor for, 120:1563–c
Metformin, prevention of pancreatic cancer induction (hamster), 120:1072–tmig, 120:1263, 120:1291–e
Methotrexate
for maintenance of remission in Crohn's disease, 120:1553–ss
sensitivity, in gastrointestinal cancer, LST-2 and, 120:1689
***N*-Methyl-D-aspartate (NMDA) receptors,** peripheral, in visceral nociception (rat), 120:1737
Methylprednisolone, for ulcerative colitis, comparison with unfractionated heparin, 120:1306–c, 120:1307–c
***MICA* alleles,** and primary sclerosing cholangitis, 120:1475
β_2-microglobulin, somatic mutation of, and unfavorable prognosis in GI cancer of microsatellite mutator phenotype, 120:1565–c
Microsatellite instability
as prognostic indicator in chemotherapy for colorectal cancer, 120:1309–c
screening for, in detection of hereditary nonpolyposis colorectal cancer, 120:1–tmig, 120:21
Microsatellite mutator phenotype, gastrointestinal cancer with, somatic mutation of β_2-microglobulin gene and unfavorable prognosis in, 120:1565–c
Migraine, abdominal, 120:263–aga
Mitochondria, abnormalities of, and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281–e
Motilin-related peptide
and ghrelin, 120:587–c, 120:588–c
identification and characterization of, 120:587–c, 120:588–c
Mucosa
gastric
adaptive cytoprotection in, PGI_2 and CGRP in, 120:134
prostaglandin production in, COX-2 inhibitors and, 120:784–tmig, 120:867
gastrointestinal, in HIV-1 infection, 120:607
Mucosa-associated lymphoid tissue (MALT), gastric, low-grade lymphoma of, 120:1884–c
Mucosal immunity, HAART and, 120:984–cr
Multidrug resistance 3 gene *(MDR3),* defect
and cholesterol cholelithiasis, 120:1459, 120:1549–e
in progressive familial intrahepatic cholestasis type 3, 120:1448, 120:1549–e
Multiple sclerosis (MS), hepatitis B vaccine and, 120:1880–ss
Muscular dystrophy, *mdx* mouse model of, mechanical tone of colon in, calcium influx and, 120:1430
Mycophenolate, for autoimmune hepatitis, 120:1502–srr

Nabumetone, gastrointestinal events related to, risk of, 120:594
Na^+/H^+ exchanger. *See* Sodium/hydrogen antiporter (sodium/hydrogen exchanger)
Naproxen, gastrointestinal events related to, risk of, 120:594
Nausea and vomiting
AGA medical position statement on, 120:261–aga
AGA technical review on, 120:263–aga
chemotherapy-related, 120:263–aga
clinical approach to, 120:263–aga
differential diagnosis of, 120:263–aga
functional, 120:263–aga
intractable, with gastroparesis, 120:263–aga
management of, 120:263–aga
postoperative, 120:263–aga
radiation-related, 120:263–aga
socioeconomic effects of, 120:263–aga
Near-infrared imaging, 120:749
Nelfinavir, GI toxicity and GI-associated drug interactions of, 120:607
Neurotensin, and jejunal bile acid absorption (rat), 120:151

Nevirapine, GI toxicity and GI-associated drug interactions of, 120:607
Nitric oxide, and oxidative DNA damage in cholangiocytes, 120:190
Nitric oxide synthase (NOS), inducible, stimulation by NF-κB, and protection against TNF-α and Fas-mediated apoptosis in hepatocytes (mouse), 120:1251
Nociception, visceral, peripheral NMDA receptors in (rat), 120:1737
Nonalcoholic steatohepatitis, insulin resistance and mitochondrial abnormalities in, 120:1183, 120:1281–e
Non-nucleoside reverse transcriptase inhibitors, GI toxicity and GI-associated drug interactions of, 120:607
Nonsteroidal anti-inflammatory drugs (NSAIDs)
gastrointestinal events related to
risk factors for, 120:594
strategies for decreasing, 120:594
and *Helicobacter pylori,* 120:594
inflammation induced by, vascular anatomy in, 120:1885–c
use in high-risk patients, 120:594
Norvir. *See* Ritonavir
Nuclear factor κB, activation of
by *Cryptosporidium parvum,* in biliary epithelia, and prevention of epithelial cell apoptosis, 120:1774
and iNOS, in TNF-α and Fas-mediated apoptosis in hepatocytes (mouse), 120:1251
Nuclear receptors, orphan, and cholesterol and bile acid metabolism, 120:1054–ss
Nucleoside analogs
GI toxicity and GI-associated drug interactions of, 120:607
therapy with, for hepatitis B, 120:1828–srr
Nucleoside reverse transcriptase inhibitors, GI toxicity and GI-associated drug interactions of, 120:607
Nutrition
advances in (future directions for), 120:1319–gn
in short-bowel syndrome, GLP-2 administration and, 120:783–tmig, 120:806, 120:1041–e

Obesity
classification of, 120:669
comorbidities in, 120:669
and insulin resistance, in pancreatic carcinogenesis, 120:1072–tmig, 120:1263, 120:1291–e
management of, advances in (future directions for), 120:1319–gn
medical therapy for, 120:669
surgical therapy for, 120:669
Obstetrics, hepatitis C and, 120:1555–ss
Octreotide
for acute variceal bleeding, meta-analysis of, 120:946
effects on portal hypertension, 120:2–tmig, 120:161, 120:303–e
effects on portal hypertension (rat), 120:975
Omeprazole, and nonacid GERD, 120:1599
Oncology, clinical, 120:583–pmr
Optical coherence tomography, 120:749
in diagnosis of specialized intestinal metaplasia, 120:1–tmig, 120:7
Organic anion-transporting polypeptide B (OATP-B), functional comparison with other OATPs of human liver, 120:525
Organic anion-transporting polypeptides, expression cloning and functional tests of, 120:1887–c
Orlistat, for obesity, 120:669
Oxidants, and Cl^- secretion in intestinal epithelial T84 cells, 120:2–tmig, 120:89
Oxidative stress, and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281–e

Pacemakers, intestinal, organization of, 120:319–co
Pain, visceral, peripheral NMDA receptors in (rat), 120:1737
Pancreas
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
structural imaging of, in diagnosis of pancreatitis, 120:682
Pancreatic acinar cells, digestive enzyme secretion by, apical actin and, 120:1818
Pancreatic cancer
association with obesity and insulin resistance, 120:1072–tmig, 120:1263, 120:1291–e
induction of, prevention of, by metformin (hamster), 120:1072–tmig, 120:1263, 120:1291–e
SST2 gene polymorphism and, 120:200
Pancreatic secretory trypsin inhibitor
gene mutations, in idiopathic chronic pancreatitis, 120:1061–c
mutations, and chronic pancreatitis, 120:682
Pancreatitis
acute
initial episode of, evaluation during, 120:708
recurrent, 120:682
causes of, 120:708
inciting factors, identification and elimination of, 120:708
severe, 120:682
chronic
autoimmune, 120:682
classification of, 120:682
clinical manifestations of, 120:682
diagnosis of, 120:682, 120:708
epidemiology of, 120:682
etiology of, 120:682
genetic predispositions to, 120:682
idiopathic, 120:682
PTSI gene mutations in, 120:1061–c
minimum change, 120:682
obstructive, 120:682
risk factors for, 120:682
SPINK1 mutations in, 120:1060–c
staging of, 120:682
tropical, 120:682
ERCP-induced, protection against, by IL-10, 120:332–tmig, 120:498
Paracentesis
for ascites, rationale for, 120:726
for refractory ascites, 120:311–ss, 120:726
Pediatrics
acute diarrhea in, management of, 120:783–tmig, 120:799
IBS in, 120:1–tmig, 120:31, 120:287–e
Peroxisome proliferator activator receptor(s) (PPAR), PPARγ, and anti-inflammatory activity in ischemia-reperfusion injury (mouse), 120:332–tmig, 120:460
p53 gene
and hepatocarcinogenesis, 120:1763
in ulcerative colitis, and cancer, 120:1877–ss
Pheochromocytoma, radiologic appearance of, 120:6–im
Phosphatidylinositol 3-kinase
bile acid-activated pathway, inhibition of Fas-mediated apoptosis in rodent hepatocytes, 120:1810
and HT29 and Caco-2 intestinal cell differentiation, 120:1317–tmig, 120:1381, 120:1543–e
and TNF-α-induced COX-2 expression in colonic epithelial cells, 120:1117

Phospholipase A_2 (PLA_2), and cholesterol absorption (mouse), 120:1193
Photodynamic diagnosis, 120:749
Photodynamic therapy
for Barrett's esophagus, persistent genetic abnormalities after, 120:1064–c, 120:1065–c
in Barrett's esophagus, 120:785–gn
Piroxicam, gastrointestinal events related to, risk of, 120:594
$p27^{Kip1}$, in human intestinal cell differentiation, 120:423
Politics and publishing
Bush administration and gastroenterology, 120:333–gn
FDA seeks to increase access to information on xenotransplantation, gene therapy trials, 120:786–gn
and Medicare regulations, 120:1320–gn
and student loan burden, 120:1320–gn
Polyps, colorectal, transition to colorectal carcinoma, *APC* gene I1307K mutation and, 120:331–tmig, 120:392
Portal hypertension
complications of, current management of, 120:726
effects of octreotide on, 120:2–tmig, 120:161, 120:303–e
effects of octreotide on (rat), 120:975
Portal vein, thrombosis
anticoagulant therapy for, 120:490, 120:578–ss
increased levels of factor VIII:C as risk factor for, 120:1563–c
Potassium channels, KCNQ1, in gastric acid secretion, 120:1363
Powell, Don W., presentation of Julius M. Friedenwald Medal to, 120:1854–aga
Prebiotic therapy, in inflammatory bowel disease, 120:622
Preveon. *See* Adefovir dipivoxil
Primary sclerosing cholangitis, *MICA* polymorphism in, 120:1475
Primum non nocere, postapproval drug surveillance and, 120:5–ce
Print and Media Reviews
Atlas of Gastrointestinal Endoscopy & Endoscopic Biopsies, 120:1304
Atlas of the Liver, 120:1304
Development of the Gastrointestinal Tract, 120:1883
Evidence Based Gastroenterology and Hepatology, 120:1559
Fast Facts: Irritable Bowel Syndrome, 120:1559
Gastroesophageal Reflux Disease, 120:583
Gastrointestinal Motility, 120:1056
Inflammatory Bowel Disease: Clinical Diagnosis and Management, 120:1057
Inner Hygiene: Constipation and the Pursuit of Health in Modern Society., 120:317
Liver Disease: Diagnosis and Management, 120:584
My Mom Has Hepatitis C, 120:1056
Positive Options for Crohn's Disease, Self-Help and Treatment., 120:317
Selected Topics in Clinical Oncology, 120:583
Probiotic therapy, in inflammatory bowel disease, 120:622, 120:1297–ss
Proctitis/proctocolitis of infancy, dietary protein–induced, 120:1026–aga
Progressive familial intrahepatic cholestasis type 3, multidrug resistance 3 gene *(MDR3)* defect in, 120:1448, 120:1549–e
Prokinetic agents
and bacterial translocation in cirrhosis, 120:314–ss
for nausea and vomiting, 120:263–aga
Proleukin. *See* Interleukin(s), IL-2
Propranolol, and bacterial translocation in cirrhosis (rat), 120:314–ss
Prostacyclin (PGI_2), and adaptive cytoprotection in gastric mucosa, 120:134
Prostaglandins, gastric mucosal production of, COX-2 inhibitors and, 120:784–tmig, 120:867
Protease, serine 1 (PRSS1). *See* Trypsinogen, cationic
Protease inhibitor
GI toxicity and GI-associated drug interactions of, 120:607
in prevention of hepatic fibrosis (rat), 120:1784
Protectin, *Helicobacter pylori* bound to, protection from complement lysis, 120:332–tmig, 120:470
Protein kinase C (PKC), PKC-δ, and colon carcinogenesis, 120:1700, 120:1868–e
Prothrombin gene, G20210A mutation, and portal or hepatic venous thrombosis, 120:1059–c
Proton pump, as target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis, 120:377
Prucalopride, for functional constipation, 120:331–tmig, 120:354
Psychotropic agents, in treatment of irritable bowel syndrome, 120:652
Public policy
Bush administration and gastroenterology, 120:333–gn
HCFA policy hurts gastroenterologists and Medicare patients, AGA charges, 120:3–gn
Racecadotril, in acute diarrhea in children, efficacy and tolerability of, 120:783–tmig, 120:799
Radiation therapy, nausea and vomiting caused by, 120:263–aga
Raman spectroscopy, 120:749
Rapid Communications
Germline variants of *EXO1* gene in patients with atypical hereditary nonpolyposis colorectal cancer, 120:1580
Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin, 120:337
Rectum
hypersensitivity, in childhood, 120:31, 120:287–e
primary squamous cell carcinoma of, HPV type 16 and, 120:988–cr, 120:1046–e
Rehydration therapy, in acute diarrhea in children, 120:783–tmig, 120:799
Reimbursement, HCFA policy and, 120:3–gn
Renal failure, chronic, and chronic pancreatitis, 120:682
Rescriptor. *See* Delavirdine
Research
funding for
in Germany, 120:334–gn
in Japan, 120:1074–gn
on gene therapy, public access to, 120:786–gn
on xenotransplantation, public access to, 120:786–gn
Retinoblastoma pathway, in colonic adenomas, 120:1680
Retinoic acid, metabolism, ethanol-induced CYP4502E1 and (rat), 120:179
Retinoid X receptor, and cholesterol and bile acid metabolism, 120:1054–ss
Retrovir. *See* Zidovudine
Ritonavir, GI toxicity and GI-associated drug interactions of, 120:607
Rofecoxib, and human gastric mucosal prostaglandin production, 120:784–tmig, 120:867
Rokitansky, Karl von, 120:1598

***Salmonella* aortitis,** 120:1322–im
Salsalate, gastrointestinal events related to, risk of, 120:594
Santorini, Giovanni Domenico, 120:805

Saquinavir, GI toxicity and GI-associated drug interactions of, 120:607
Selected Summaries
Alcoholic steatosis: the Kupffer cell a villain?, 120:581
Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy, 120:576
Bile acids regulate their own synthesis: the nuclear connection, 120:1557
Cesarean for C? Possibly. . ., 120:1555
Helicobacter eradication *versus* prompt endoscopy for dyspepsia, 120:1298
The hepatitis B vaccine: sorting through the B.S. about M.S., 120:1880
Is hepatic fibrosis reversible with therapy in hepatitis C?, 120:579
Management of gastric varices, 120:1875
Management of refractory ascites: are TIPS or taps tops?, 120:311
Manipulating intestinal cholesterol absorption and hepatic cholesterol and bile acid metabolism by activation of deorphanized nuclear receptors, 120:1054
Methotrexate for the maintenance of remission in Crohn's disease, 120:1553
Novel medical therapies for Crohn's disease: is there room for growth?, 120:308
Nutritional therapy for alcoholic hepatitis: new life for an old idea, 120:1053
p53 at the crossroads of colitis and cancer, 120:1877
Predicting the outcome of hepatitis C virus infection, 120:312
The prevention of hepatocellular carcinoma by interferon: the story continues, 120:1301
Prokinetics reduce bacterial translocation in cirrhosis: will sweeping the gut keep the fluid clean?, 120:314
The road not taken, 120:1878
Single-stage operations for Hirschsprung's disease – pushing the envelope, 120:1299
Treatment of hepatoportal venous thrombosis: the role of anticoagulation, 120:578
Turbo probiotics for IBD, 120:1297
What lies beyond the view of the sigmoidoscope?, 120:1051
What's right and what's left?, 120:1049
Selectins, differential role of, in experimental colitis, 120:1072–tmig, 120:1162
Selective serotonin reuptake inhibitors (SSRIs), in treatment of irritable bowel syndrome, 120:652
Sepsis, hepatobiliary dysfunction in, protective role of carbon monoxide from heme catabolism in (rat), 120:1227, 120:1288–e
Serine protease, and digestive enzyme secretion in pancreatic acinar cells, 120:1818
Serine protease inhibitor, Kazal type 1 (SPINK1). *See also* Pancreatic secretory trypsin inhibitor
gene mutations, in chronic pancreatitis, 120:1060–c
Short-bowel syndrome, treatment of, glucagon-like peptide 2 in, 120:783–tmig, 120:806, 120:1041–e
Sibutramine, for obesity, 120:669
Sigmoidoscopy, limitations of, 120:1049–ss, 120:1051–ss
Sildenafil, therapy with, in animal models of diabetic gastropathy, 120:576–ss
Small intestine
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
motility, GRP receptor blockade and, 120:331–tmig, 120:361
muscle in, tachykinin receptor NK_1 on, immunohistochemical demonstration of (guinea pig), 120:1140
Smoking, and chronic pancreatitis, 120:682
Smoking cessation, and course of Crohn's disease, 120:1071–tmig, 120:1093
Smooth muscle, enteric, persistent postinfective dysfunction, immunologic factors and COX-2 in (mouse), 120:1713
Smooth muscle antibody, in liver disease, 120:239–srr
Smooth muscle relaxants, in treatment of irritable bowel syndrome, 120:652
Sodium/hydrogen antiporter (sodium/hydrogen exchanger)
and hepatic fibrosis (rat), 120:545, 120:572–e
and hepatic stellate cell activation (rat), 120:545, 120:572–e
Somatostatin receptor gene, polymorphism, in human pancreatic cancer cells, 120:200
Special Reports and Reviews
Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease, 120:1009
Autoantibodies in liver disease, 120:239
Autoimmune hepatitis: clinical challenges, 120:1502
Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map, 120:221
Immunology of the healthy liver: old questions and new insights, 120:250
The lymphoid liver: considerations on pathways to autoimmune injury, 120:1485
Management of hepatitis B: 2000—summary of a workshop, 120:1828
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection, 120:1000
Spectroscopy, for evaluation of dysplasia in Barrett's esophagus, 120:1607
Splenic vein, thrombosis, increased levels of factor VIII:C as risk factor for, 120:1563–c
Spontaneous bacterial peritonitis
acute, treatment of, 120:726
current management of, 120:726
primary prophylaxis for, 120:726
recurrent, prevention of, 120:726
Squamous cell carcinoma, primary rectal, HPV type 16 and, 120:988–cr, 120:1046–e
Stavudine, GI toxicity and GI-associated drug interactions of, 120:607
Stellate cells, hepatic
activation of, Na^+/H^+ exchanger and (rat), 120:545, 120:572–e
apoptosis in, peripheral-type benzodiazepine receptor expression and, 120:1212, 120:1285–e
Stensen, Niels, 120:38
Steroids, for ulcerative colitis, comparison with unfractionated heparin, 120:1306–c, 120:1307–c
Stimulator of Fe transport (SFT), duodenal expression of, in anemia and hemochromatosis, 120:1404
Stomach
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
human antral gastrin cells, calcium-sensing receptor in, mechanism of action of, 120:1128, 120:1279–e
low-grade MALT lymphoma of, 120:1884–c

Stress, and induction of EGF-like growth factors in gastric epithelial cells (rat), 120:108
Student Loan Interest Deduction Act, 120:1320–gn
Sucrase-isomaltase, as epithelial cAMP-dependent chloride channel, 120:117, 120:299–e
Superoxide dismutase
mitochondrial targeting sequence of, homozygosity for alanine in, and risk for alcoholic liver disease, 120:1318–tmig, 120:1468
and reduction of alcohol-induced liver injury (rat), 120:1241
Sustiva. *See* Efavirenz

Tachykinin receptor, NK_1, immunohistochemical demonstration of, on intestinal muscle and epithelia (guinea pig), 120:1140
Tachykinins
and nerve-mediated contractions in human esophagus, 120:1–tmig, 120:39
and peristalsis in isolated distal colon (guinea pig), 120:938
Tacrolimus, for autoimmune hepatitis, 120:1502–srr
Tartikoff, Lily, and CRC screening, 120:333–gn
3TC. *See* Lamivudine
T cells (T lymphocytes)
$CD4^+$
of lamina propria, HIV-1 infection and, 120:607
mucosal, HAART-related increase in, 120:984–cr
$CD8^+$, apoptosis, in liver, 120:250–srr
and colitis, in Tgε26 mice, 120:900
development of, in liver, 120:250–srr
Th1-type cytotoxic, H^+,K^+-ATPase–specific, in autoimmune gastritis, 120:377
Telangiectasia, bleeding, of gastrointestinal tract, abnormal von Willebrand factor in, 120:346
Thalidomide therapy, cessation of, intractable insomnia after, 120:1567–c
This Month in GASTROENTEROLOGY
Acute diarrhea in children: is rehydration therapy enough?, 120:783
APC 1307K and the risk of colorectal cancer, 120:331
Can baseline adenoma characteristics predict the recurrence of advanced adenomas?, 120:1071
Cereal fiber may reduce the risk of gastric cardia cancer, 120:331
Colonic luminal contents induce cyclooxygenase 2 transcription, 120:332
COX-2 inhibits spare gastroprotective prostaglandins, 120:784
Do genes determine susceptibility to alcoholic liver disease?, 120:1318
Effect of duodenal iron absorption on iron homeostasis, 120:1317
Effects of octreotide on portal hypertension, 120:2
Endogenous PPARγ mediates inflammation in ischemia-reperfusion injury, 120:332
Esophageal manometry for the diagnosis of achalasia, 120:783
Family history of colorectal cancer may increase IBD-associated CRC, 120:1317
Fat digestion modulates gastrointestinal symptoms, 120:1071
Glucagon-like peptide 2 administration for the treatment of short-bowel syndrome, 120:783
Hepatitis C viral kinetics and peginterferon α2a, 120:1318
Human papilloma virus and the risk of anal canal cancer, 120:784
IBD and the risk for colorectal cancer, 120:783
Interleukin 10 reduces postherapeutic ERCP-induced pancreatitis, 120:332
Irritable bowel syndrome in children, 120:1
Localization of mutant Wilson disease protein, 120:784
Mechanisms for gastrointestinal motility, 120:331
Microsatellite instability and genetic testing for HNPCC, 120:1
New treatment modalities for inflammatory bowel disease, 120:1317
Optical coherence tomography in the diagnosis of specialized intestinal metaplasia, 120:1
Oxidants potentiate agonist-induced Cl^- secretion in intestinal epithelial T84 cells, 120:2
Pancreatic cancer and obesity, 120:1072
Phosphatidylinositol 3-kinase and intestinal differentiation, 120:1317
Predictors for relapse in ulcerative colitis, 120:1
Prognostic value of measuring circulating colorectal cancer cells, 120:1071
Protectin-bound *H. pylori* prevents complement-induced lysis, 120:332
Prucalopride for the treatment of functional constipation, 120:331
Role of tachykinins in nerve-mediated contractions in the human esophagus, 120:1
Selectins in experimental colitis, 120:1072
Smoking cessation and Crohn's disease, 120:1071
Thrombophilic gene mutations, and portal or hepatic venous thrombosis, 120:1059–c
Time-resolved fluorescence, 120:749
Toxins, and chronic pancreatitis, 120:682
Toxoplasmosis, ileitis after, regulation by TGF-β-producing intraepithelial lymphocytes (mouse), 120:914
Transepithelial signaling, in human stomach, 120:1128, 120:1279–e
Transferrin receptor, duodenal expression of, in anemia and hemochromatosis, 120:1404
Transforming growth factor β (TGF-β)
in hepatic fibrosis (rat), 120:1784
and regulation of ileitis after intracellular parasite infection (mouse), 120:914
Transgenic mice
cell-specific targeting of genes in, keratin 19 promoter for, 120:1728
keratin 19, 120:1728
Transjugular intrahepatic portosystemic shunt (TIPS), for refractory ascites, 120:311–ss
Trypsinogen, cationic, gene mutations, and chronic pancreatitis, 120:682
Tuberculosis, ileocecal, 120:1076–im
Tumor necrosis factor, engineered human antibody to (CDP571), for active Crohn's disease, 120:1317–tmig, 120:1330

Ulcerative colitis (UC)
backwash ileitis in, and colorectal cancer risk, 120:783–tmig, 120:841
p53 gene in, and cancer, 120:1877–ss
refractory, laparoscopic appendectomy with, 120:1562–c
relapse in, predictors of, 120:1–tmig, 120:13
treatment of, IV cyclosporine *versus* IV corticosteroids as single therapy for, 120:1317–tmig, 120:1323, 120:1541–e
Ulcerative enteritis, in celiac disease, 120:1526–aga
Ursodiol, and impaired liver sinusoidal bile acid uptake in Amish kindred, 119:321–co

Vagus nerve, and motor control of lower esophageal sphincter, GABAB receptors in, 120:1749
Variceal bleeding
acute
octreotide for, meta-analysis of, 120:946
treatment of, 120:726
endoscopic sclerotherapy for, complications of, 120:336–im
first episode of, prevention of, 120:726
gastric, management of, 120:1875–ss
recurrent, prevention of, 120:726
Varices, prevention of, 120:726
Vasoconstriction, PKC-dependent, in portal hypertension, octreotide and (rat), 120:975
Videx. *See* Didanosine
Viracept. *See* Nelfinavir
Viramune. *See* Nevirapine
Vomiting. *See also* Nausea and vomiting
cyclic, 120:263–aga
von Hippel-Lindau (VHL) disease, 120:788–im
von Willebrand factor, abnormalities of, in gastrointestinal bleeding angiodysplasias, 120:346

Walsh, John, 120:335–ce
Wilson disease, ATP7B protein mutants in
localization of, 120:784–tmig, 120:967
properties of, 120:784–tmig, 120:967

X chromosome, inflammatory bowel disease susceptibility locus on, 120:834
Xenotransplantation
information on, FDA seeks to increase access to, 120:786–gn
of liver, 120:749

Zalcitabine, GI toxicity and GI-associated drug interactions of, 120:607
ZDV. *See* Zidovudine
ZDV-3TC, GI toxicity and GI-associated drug interactions of, 120:607

Ziagen. *See* Abacavir

Zidovudine, GI toxicity and GI-associated drug interactions of, 120:607

Zollinger-Ellison syndrome, lung cancer and, 120:1271–cr